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ABSTRACT

Aslam Kiran. Ph.D., Purdue University, August 2016. Deciphering the Role of Hsp31 as
a Multitasking Chaperone Protein Major Professor: Tony Hazbun.
Among different type of protein aggregation, amyloids are biochemically well
characterized state of protein aggregation that is commonly associated with a large
number of neurodegenerative diseases in mammals and cause heritable traits in
Saccharomyces cerevisiae. Among many other neurodegenerative diseases linked with
amyloids, Parkinson’s disease is the second most common disorder that is caused by
progressive deterioration of dopaminergic neurons in substantia nigra. Cellular stresses
such as accumulation of high level of reactive oxygen species, mitochondrial dysfunction
and α-syn aggregation lead to toxicity and neuronal cell death in Parkinson’s disease
patients. Mutations in certain genes are also involved in the development of a familial
form of PD including PARK7 that encodes DJ-1. DJ-1 is a member of ThiJ/DJ-1/PfpI
protein superfamily that are the quintessential multitasking or moonlighting protein
family as evidenced by their involvement in multiple cellular functions including
oxidative stress sensing, protein folding, proteasome degradation, mitochondrial complex
stabilization, methylglyoxalase and deglycation enzyme activities. The members of the
ThiJ/DJ-1/Pfp1 superfamily appear to have evolved to numerous mechanisms to manage
cellular stress. The protein superfamily members are present across the evolutionary
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spectrum including prokaryotes and the budding yeast, S. cerevisiae, that has four
paralogs Hsp31, Hsp32, Hsp33, and Hsp34. Hsp31 consists of 237 amino acids with a
MW of 25.5 kDa and forms a homodimer in solution. It possesses the Cys-His-Glu
catalytic triad common to ThiJ/DJ-1/PfpI superfamily proteins. Previously, we have
shown that Hsp31 possesses chaperone properties with protective effects against α-syn
toxicity in yeast. Recently, it is shown that Hsp31 has a methylglyoxalase activity that
converts the toxic metabolite methylglyoxal into lactate. Here, we confirmed that Hsp31
is a robust methylglyoxalse that is more potent in activity than its human homolog DJ-1.
We demonstrated that Hsp31 chaperone activity to protect the cells from α-syn toxicity is
not under the influence of its enzymatic activity or autophagy pathway. Moreover, we
confirmed that Hsp31 expression is induced by H2O2 mediated oxidative stress and
further showed an increased expression of Hsp31 under α-syn mediated proteotoxic stress.
These results establish that Hsp31 molecular chaperone activity is self-sufficient to
protect the cells from stress conditions without requiring its enzymatic activities.
Another associated class of amyloid aggregation state includes prions, which are selfreplicating, misfolded proteins capable of adopting amyloid aggregates in cells. In yeast,
[PSI+] prion is the aggregated form of translation termination factor Sup35. Sup35, a
translation-termination factor, is one of the original and best-studied prions in yeast. In
the present study, we established the role of Hsp31 in preventing Sup35 aggregation both
in vivo and in vitro using fluorescence microscopy, flow cytometry and SDD-AGE
respectively. In addition, we provide evidence that Hsp31 act early on in the process of
protein aggregation, as we didn't observe any co-localization of Hsp31 with larger Sup35
prion aggregates. Moreover, Hsp31 transiently prevents prion induction with no
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significant reduction over a prolonged induction of Sup35 aggregation indicating that
Hsp31 acts prior to the formation of larger aggregates. This was further confirmed, as an
elevated level of Hsp31 by itself was unable to cure [PSI+] prion with formerly present
large aggregates. We established that Hsp31 inhibit Sup35 [PSI+] prion formation in
collaboration with a well-known disaggregase, Hsp104. Hsp31 inhibits Sup35 aggregates
formation and potentiates [PSI+] prion curing by overexpression of Hsp104. Absence of
Hsp31 reduce the rate of [PSI+] prion curing by Hsp104 without influencing its ability to
rescue the cell by thermotolerance. We also showed that Hsp31 physically interact with
Hsp104 and together they prevent Sup35 prion toxicity to greater extends than if they
were expressed individually in the yeast. These results elucidate a mechanism of Hsp31
on prion modulation that could have implication in many neurodegenerative diseases.
Taken together, the results show that Hsp31 is a stress-inducible protein with chaperone
and glyoxylase activity that acts on a wide spectrum of misfolded proteins including αsyn and Sup35. These studies set the stage for further mechanistic insight in the
biological roles of the Hsp31/DJ-1 chaperone family.
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CHAPTER 1. INTRODUCTION

1.1

High-fidelity protein quality control

Biogenesis of protein is carefully monitored by protein quality control (PQC) process to
avoid sporadic errors or damage ring during the synthesis or life times of cellular proteins.
In order to maintained protein homeostasis, damaged proteins must be corrected or
degraded after synthesis (1-5). These two types of defense mechanisms are mediated by a
complex network of chaperones, the ubiquitin–proteasome system (UPS) and autophagy
mediated-lysosomal proteolysis (2,4,6). Chaperones bind newly synthesized proteins as
well as unfolded proteins to assist them in reaching a mature protein conformation at the
expense of ATP hydrolysis (2,7,8). Moreover, ubiquitin ligases that are recruited by
chaperones, will themselves degrade damaged proteins that are beyond repair (2,6,8,9). In
addition, PQC monitors the cell to ensure proper folding of mature proteins that have the
tendency to revert into native conformation under oxidative or proteotoxic stress (3,10).
Similarly, additional quality control systems will ensure the proper synthesis of other
macromolecules such as DNA and RNA (1,3,11,12). The PQC process occurs throughout
the cell and is classified according to the location of the misfolded substrate in different
cellular compartments (7). Therefore, the PQC system plays a vital role in maintaining
the proper folding of proteins and it has significance in
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the pathophysiology of diseases associated with protein misfolding and aggregation
(13,14).
1.1.1

Consequences of Protein Misfolding

Virtually all aspect of biological life processes is determined by highly diverse enzymatic
and the structural characteristics of proteins. On the other hand, protein can be a
vulnerable entity for living cells if there is extensive change in their structural
conformation (15-18). The alpha helical spiral coils are the most common secondary
structure in proteins that must be maintained to their native conformation, in order to be
biochemically functional. Although, many functional native proteins contain beta sheets,
a protein becomes toxic if it acquires an abnormal conformational transition from alpha
helix to beta sheet (19-22). Partially folded or misfolded proteins expose their
hydrophobic amino acids and unstructured polypeptide to promote protein aggregation in
a concentration dependent manner. Such misfolding or partial folding leads to association
of proteins with each other to form protein aggregates that further accumulate together to
form larger aggregates (23,24). While, hydrophobic forces driving the formation of
smaller aggregates primarily leads to larger amorphous aggregates, it can also guide to
the formation of highly structured protofibrils known as amyloids that possess distinct
cross β-strands and are thermodynamically stable (16,21,25).
1.1.2

Role of chaperone in protein homeostasis

Amino acid sequences of any protein encoded by DNA, contains all the fundamental
information required to fold a protein into a three-dimensional structure, as small proteins
can refold in vitro from a denatured state without needing other components or energy
sources (3). However, research over the past 20 years has revealed that many proteins
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particularly large proteins require molecular chaperones to fold effectively and in a
timely manner in vivo (26,27). Chaperones can be defined as a protein that binds and
stabilizes another protein to achieve its functionally active conformation. Chaperones
form a complex network of many different classes of structurally unrelated proteins that
cooperate together in cells to maintain protein homeostasis (28). Members of these
families are often up regulated under conditions of stress in which the concentration of
partially folded protein intermediates are increased. They are often known as heat shock
proteins (HSPs) or stress proteins and named after their molecular weights such as Hsp40,
Hsp60, Hsp70, Hsp90, Hsp100 and small HSPs (27,29-33). They are involved in multiple
functions of protein homeostasis including de novo protein folding, oligomeric assembly,
protein trafficking, refolding of denatured proteins as well as help in proteolytic
degradation and disaggregation of larger aggregates (26,33-40). The classes of chaperone,
such as Hsp70 and Hsp90 that are involved in the de novo folding of protein require ATP
hydrolysis and multiple binding and release of co-chaperones. They also cooperate with
ATP-independent chaperones, such as small HSPs to facilitate protein disaggregation
(33,34,36,37). In the de novo folding of proteins, ATP-dependent chaperones usually
bind to exposed or accessible hydrophobic amino acids of a non-native protein to
transiently prevent aggregation driven by ATP hydrolysis. ATP hydrolysis is facilitated
by co-chaperones such as Hsp40, that mediate Hsp70 recruitment to substrate proteins,
Hsp40 also interacts with partially folded protein substrate to unfolded peptides. After
release of the substrate protein from co-chaperones, Hsp70 rebinds to the peptides until
they achieve their functional folded state and therefore prevent them from aggregation
(26).
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Another role of chaperones in maintaining protein homeostasis is to regulate protein
concentration in the cells. During the folding process, chaperones stabilize protein
molecules and ultimately increase their concentration to achieve the cells need and
similarly, when a particular protein is not in demand chaperones diminish the folding
process with the help of regulator proteins to decrease its concentration. Although the
primary role of the chaperone machinery is during the initial protein folding process, it is
now being accepted that many proteins depend on molecular chaperones assistance to
maintain or regain their functionally active conformations throughout their cellular life
(26,41).
1.1.2.1 Heat Shock Proteins
Italian geneticist Ferruccio Ritossa first discovered the first evidence of heat shock
proteins in 1962. He reported that heat shock treatment of Drosophila larvae induces a
puff pattern in the polytene chromosomes that was later was identified and associated
with the synthesis of heat-shock proteins that are now commonly known as molecular
chaperones (42,43). These proteins are highly upregulated under stress conditions such as
environmental, metabolic or pathophysiological stress and play a vital role in the survival
of cells under such conditions. These proteins are highly conserved across species and
generally classified according to their molecular masses into six major families i.e.
Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and small heat shock proteins (sHSPs) (44-46). A
list of major HSPs along with their cellular location and brief description of primary
functions is outlined in Table 1.1.
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Table 1.1 Major heat shock proteins: subcellular location and functions.
Heat-shock protein

Subcellular

Known functions

localization
Hsc70

Cytosol/nucleus

Protein folding, clathrin uncoating,
peptide binding

Hsc74

Mitochondria

Involved in antigen presentation and
radioresistance. Also oncogenic
(overexpression of Mot-2 leads to p53
inactivation and cell transformation).

Hsp110

Cytosol/nucleus

Binds to Hsc70 to form highmolecular-weight complex; involved in
protein folding, thermotolerance, and
embryogenesis

Hsp27

Cytosol

Antiapoptotic, cytoprotection

Hsp40

Cytosol

Repair denatured proteins, together
with Hsp70/Hsc70

Hsp60

Mitochondria

Cytoprotection; macrophage activator
possibly through Toll-like receptors

Hsp70

Cytosol/nucleus

Cytoprotection and anti-apoptotic,
Hsp70-2 implicated in spermatogenesis

Hsp90α

Cytosol

Protein folding, peptide chaperone,
cytoprotection, intracellular signaling
(e.g., steroid receptor), cell-cycle
control and buffering of harmful
mutations

Hsp90β

Cytosol

Major cytosol chaperone; protein
folding; cytoprotection; intracellular
signaling (e.g., steroid receptor); cellcycle control; and buffering of harmful
mutations
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1.1.2.2 Small heat shock proteins
The sHSPs are phylogenetically widespread and have been found in almost all organisms
ranging from archaebacteria, prokaryotes and eukaryotes. Within cells, they are found in
multiple subcellular locations where they bind to wide range of unfolded proteins
substrates to prevent their aggregation (44,47-49). Proteins in this family possess 12-43
kDa weights with the ability to form dynamic oligomers. Monomers of many sHSPs are
composed of a conserved 80-100 amino acid α-crystallin domain, accompanied with
beta-strands responsible for dimerization. The N-terminal domain is responsible for
oligomerization, phosphorylation and chaperone activity but it is not a highly conserved
domain, while the C-terminal domain is accountable for client protein interaction,
nucleotide binding and homodimerization (48). In vitro studies revealed that quaternary
structures of sHSPs are very stable and can binds to large number of unfolded protein
substrates compared to other major chaperones. sHSPs are consider as having ‘holdase’
activity because of their unusually high tendency to bind unfolded client proteins and to
assist subsequent refolding of substrates by ATP-dependent chaperone networks (44,48).
Structural and in vitro studies have led to a proposed model that under stress conditions,
oligomers of sHSPs undergo structural rearrangement and breakdown into monomers to
be functionally active. Although the exact mechanism is poorly understood, it is thought
that the hydrophobic regions of sHSPs may bind with hydrophobic surfaces of partially
misfolded proteins to make larger soluble complexes that inhibit further aggregation of
the misfolded proteins (50-52).
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The sHSP family displays a functional diversity such as protecting the cells from stressful
conditions, involvement in stress tolerance, protein folding, protein degradation,
maintaining cytoskeletal integrity, cell cycle, signal transduction, cell differentiation and
cell death. Moreover, many members of sHSP family interact with their substrates to
display potent anti-apoptotic activity and anti-inflammatory property as well as exhibit
cardio and neuroprotection (44,47,53). Therefore, sHSP family members have important
implications in a broad range of health and disease conditions. However, many
unanswered questions remain regarding the underlying mechanisms of sHsps pleiotropic
functions and their promiscuous interactions.
1.2

Neurodegenerative diseases

Several common pathways have been proposed to cause the underlying etiology and
pathology of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), Fronto-temporal dementia (FTD), Amyotrophic Lateral Sclerosis (ALS),
and Prion diseases (54). Multiple factors have been implicated in causing
neurodegeneration such as protein misfolding leading to aggregation, mitochondrial
dysfunction, free radical formation caused by oxidative stress and environmental
exposure of metals and pesticides associated with age (20,22,55,56). Although there is a
partial overlap in the general mechanism of these neurodegenerative diseases, each
disease has its own distinct molecular mechanism and pathological manifestation
including degradation of specific brain regions and deposits of protein aggregates in
neurons (55,57). The most common characteristic of this group of diseases is the
accumulation and deposition of aggregated or misfolded proteins including α-synuclein
(α-syn) in PD, amyloid-β in AD, huntingtin protein in HD and transactive response
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DNA-binding protein 43 (TDP-43) in ALS (54,56-61). A list of aggregation associated
neurodegenerative diseases are outlined in Table 1.2.
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Table 1.2 Aggregation associated neurodegenerative diseases.
Disease

Associated

Protein deposits

protein/gene
Alzheimer’s disease

Most affected
regions

Amyloid beta,

Extracellular

Cortex,

APP

Plaques

Hippocampus, basal

Tau, ApoE,

Intracellular tangles

forebrain, brain stem

PSEN1,
PSEN2
Parkinson’s disease

Huntington’s

αSyn, Parkin,

Lewy bodies

Substantia nigra,

DJ-1, UCHL-

cortex, locus

1, LRRK2

ceruleus

Huntington

disease

Huntington with poly

Striatum, other basal

glutamine expansion

ganglia, cortex

Prion disease CJD,

Sporadic,

Prion amyloid

Cortex, thalamus,

fatal familial

genetic and

plaques, Spongiform

brain stem,

insomnia)

infectious,

degeneration

cerebellum

PrPSc, PRNP
Polyglutamine

PolyQ

Nuclear and

Basal ganglia, brain

diseases (DRPLA,

containing

cytoplasmic

stem, cerebellum

GSS, SCA1-3,

proteins, Genes

inclusions

and spinal cord

SBMA etc)

with CAG
repeat
expansion
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Table 1.2 continued
Familial

SOD1

Bunina body tangles

Spinal motor

amyotrophic lateral

neurons and motor

sclerosis (ALS)

cortex

Tauopathy

Tau

Cytoplasmic

Cortex, brain stem

inclusions

and other areas

APP, amyloid precursor protein; ApoE, Apolipoprotein; PSEN1/2, Presenilin 1/2; PRNP, prion protein;
CJD, Creutzfeldt-Jakob disease; DRPLA, dentato-rubral and pallido-Luysian atrophy; GSS, GerstmannStraussler-Scheinker; SBMA, spinal and bulbar muscular atrophy; SCA, spino-cerebellar ataxia.
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1.2.1

Mitochondrial dysfunction in neurodegenerative disease

The mitochondria, most often known as powerhouses of the cells, are responsible for
most of the energy supply in eukaryotic cells. They play critical roles in regulating cell
processes including signaling pathways, calcium balances, reactive oxygen species (ROS)
formation, cell cycle regulation, thermogenesis and cell death. The loss of mitochondrial
function is associated with increased ROS production and oxidative stress that are
responsible for development of numerous neurodegenerative disorders. Mitochondria
generate adenosine triphosphate (ATP) during oxidative phosphorylation using metabolic
intermediates in tricarboxylic acid (TCA) cycle. Superoxide anion radicals (O-2) that are
produced during electron transport chain (ETC) activity are converted into hydrogen
peroxide by enzymatic action of superoxide dismutase in the mitochondria. Hydrogen
peroxide further detoxifies by the action of glutathione peroxidase into water in the
mitochondria. Defects in enzymes involved in the ETC leads to increased production of
ROS resulting in a decrease in the mitochondrial membrane potential, energy crisis and
finally cell death. In addition to antioxidant activity of mitochondrial enzymes mentioned
above, cells also possess glutathione (GSH), Vitamin E, Vitamin C and ubiquinone as
antioxidant agents that protect the cell from oxidative stress. An imbalance in the
antioxidant homeostasis leads to oxidative stress in cells (62-64). In the CNS, neurons are
particularly prone to oxidative stress resulting in accumulation of ROS that potentially
leads to the initiation of free radical chain reactions and finally cell death. Many classes
of macromolecules ranging from lipids to DNA and proteins are found to be oxidatively
damage in neurodegenerative diseases such as PD, AD, HD and ALS (56,65-67). Thus
mitochondrial dysfunction and defects in mitochondrial activity parameters including

12
alteration in mitochondrial dynamics, increase in ROS production and loss of energy
leads to neuronal death and are an important contributor in the manifestation of
neurodegenerative disorders (66). Therapeutic approaches to target mitochondrial
functions could certainly be useful however, using antioxidants, as sole therapy to treat
neurodegeneration appears to be not sufficient. In fact, several clinical studies have
demonstrated only little success with antioxidants in the treatment of neurodegeneration
(68). Targeting mitochondrial proteins to alter abnormal mitochondrial dynamics may
provide a potential therapeutic strategy against neurodegenerative diseases (64).
1.2.2

Amyloidogenesis

The term ‘amyloid’ has been used to describe the highly ordered cross beta proteinaceous
structures found in various pathological conditions. Amyloids are formed when a soluble
and innocuous protein transforms into insoluble protein aggregates that might not be
directly invasive but are associated with neuropathology. The tendency of amyloid
formation is multifactorial including amino acid composition, protein sequences and
concentration, posttranslational modification and environmental factors (16,19). Several
studies now clearly show that protein aggregation is a complex process that occurs in
several different steps, making different kinds of intermediates and finally turned into
larger aggregates that could be either amorphous or amyloids (69). However, there is
much to be learned as most of these studies are done in vitro and hence may not simulate
in vivo behavior in human diseases (70). Initiation of the multi-step pathway of protein
aggregation begins with modification of protein to an abnormal conformation that may be
a covalent modification such as cleavage or phosphorylation of the disease protein. These
modifications of proteins facilitate the conversion of monomers into smaller oligomers
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that further assemble into protofibrils. Association of these protofibril intermediates can
form larger amyloid aggregates that can be visualized under the microscope (71-76). It is
hypothesized that intermediate species are more toxic than the precursor protein or final
amyloids (73,77,78) (Figure 1.1). Therefore, it would maybe beneficial to inhibit
aggregation formation at early stages of the pathway, as it may prevent the formation of
toxic oligomeric species.
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Figure 1.1 Hypothetical pathway in the formation of amyloid.
Amyloidogenesis is considered to be a legitimate pathological reason for neuronal
degeneration although the exact mechanism behind this degeneration remains
unidentified (14,79). Several models of amyloid-associated toxicity have been proposed.
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First, amyloids occupy the extracellular space that damages the normal architecture and
function of cells and thus leads to neuronal toxicity. It is also proposed that smaller
oligomers formed at initial stages of amyloidogenesis are more toxic to cells as they
destabilize cellular membranes (16,74,80,81). These intermediate oligomers assemble
into final amyloid fibrils that have been hypothesized as a non-invasive product of the
toxic intermediates that might rather be a detoxification mechanism. Another group of
studies suggest that generation of ROS by the incorporation of redox metals into
amyloids could affect cell viability (74). On the other hand, the larger aggregates could
recruit and thus diminish some essential proteins for cell survival (82).
1.3

Parkinson’s disease

PD is an idiopathic disease of the nervous system characterized by two neuropathological
hallmarks, the preferential loss of dopaminergic neurons in the substnatia nigra pars
compacta region of the brain and the presence of cytosolic inclusions called Lewy bodies
(LBs) in various brain regions (56,58,83). It is a chronic progressive disease that affects
the older population but can also occurs in much younger patients and is the second most
common neurodegenerative disorder after AD (84,85). Dr. James Parkinson, after whom
the disease is named, first recognized PD in the early 1800’s. PD affects 10 million
people worldwide and it is expected that its prevalence in America will increase
dramatically over the next 20 years as the proportion of the population ages (86,87). In
developing nations, the life expectancy is rising and cases of such age related
neurological disorders is also increasing resulting in a strong impact on the healthcare
system and economy due to direct and indirect costs associated with care of PD patients
(84,88,89). Therefore, it is critical to understand the molecular mechanisms of PD to
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develop better therapeutic strategies, early detection of the disease and identify causative
genetic and environmental factors.
1.3.1

Risk factors

Age is the major risk factor for PD with an average age of disease onset of 60 years and
risk of diagnosis greatly increases after 85 years of age (90,91). Other risk factors include
family history and environmental stress such as exposure to pesticide toxins. Men are
more susceptible than women to develop the disease but the causative risk factor is still
unclear (92-94). Numerous other risk factors have been associated with PD though the
epidemiologic evidence is not robust. These include drinking of well water, excess milk
consumption, obesity, living in rural areas with exposure to copper, manganese, lead and
hydrocarbon solvents such as industrialized, farming or agricultural work (94-96). On the
other hand, cigarette smoking and caffeine intake have been linked with reduced risk of
PD (97). Table 1.3 describes the etiology of PD.
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Table 1.3 Etiology of Parkinson’s disease
Feature

Details

Age of onset

65

Men:women

1.5:1

Idiopathic:hereditary,%

90:10

Frequency/1000persons
Patients aged 55-65 y

0.3

Patients >85 y

4.4

Percentage prevalence
Total population

0.3

People >60 y

1

Life expectancy

Varies with the age of the onset and
occurrence of dementia

Risk factors

Age, family history, pesticide exposure and
head injury

Motor symptoms

Tremor, rigidity, bradykinesia, postural
instability, impaired speech and gait

Non motor symptoms

Constipation, autonomic dysfunction,
dementia, depression, sleep disorder and
psychosis
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1.3.2

Genetic factors

Although the majority of PD cases are sporadic, about 5-10% PD cases are familial as
they are associated with gene mutation. The number of genes associated with the onset of
early or advanced PD have steadily increased over the last 15 years including mutations
or amplification in the LRRK2, PARK2, PARK7, PINK1, or SNCA (PARK1) gene and
possibly additional unidentified genes (92,94,98). Even though most cases of PD are
sporadic, examining the genes associated with PD is valuable as there is evidence to
show a strong correlation between sporadic and familial forms of PD. PARK1 encodes αsyn consists of autosomal dominant gene, mutation or multiplication of this can lead to
PD (99,100). The α-syn protein is a 140 amino acid protein that exclusively expressed in
the CNS. Natively it is present mostly as membrane-bound α-helices in the neurons.
(101,102). In the disease form, α-syn mainly presents as an aggregated protein
component found in LBs (103). Several α-syn mutants including A53T, A30P, E46K and
H50Q have been shown to increase the aggregation formation that leads to form
potentially toxic protofibrils. High level of α-syn also sequestered several cytoskeletal
proteins, such as tubulin, that prevent the conversion of α-syn into fibrils leading to
increase in toxic protofibril species (99,100,104-107).
1.3.3

Diagnosis

Despite extensive research done on the pathophysiology of PD, its diagnosis is still
restricted to suboptimal methods for detection and prognosis. There is a critical need for
the development of highly sensitive and specific biomarkers as they are lacking currently
(108). The PD diagnostic decision in a clinic relies on the presence or manifestations of
symptoms associated with the disease such as bradykinesia, rest tremor, rigidity, postural
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instability and impaired gait (93,109-111). If patient response to dopaminergic agents
such as levodopa and patient history reveals gradual progression of symptoms there is
likelihood of accurate diagnosis of PD. However, responsiveness to levodopa has been
seen in other parkinsonian syndromes and unrelated dystonias (108,112,113). To confirm
PD, presence of Lewy bodies (LBs), protein deposits in substantia nigra and loss of
neurons is a required diagnostic criteria upon examination of a deceased patient’s brain
section (110,113). As this approach is a post mortem examination, it has no implications
in clinical diagnosis.
There are several biomarkers currently being analyzed that can correlate with PD
prognosis with high accuracy and can be used as next generation diagnostic tools (114117). Among them the major constituent of PD such as oligomeric forms of α-syn and
DJ-1 protein level have been analyzed in the blood of PD patients with no success
(107,118,119). Several other biomarkers such as uric acid level, iron level in the
substantia nigra region of brains as well as epidermal growth factor (EGF) and
Apolipoprotein A1 (ApoA1) are under investigation (120-123). Currently there is no
single biomarker available to predict PD progression with reliability and validity
(114,124).
Neurologic imaging tools such as positron emission tomography (PET) scan, magnetic
resonance imaging (MRI), ultrasonography and others play small role in diagnosis and
are presently not accepted as diagnostic tool for PD (125-127).
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1.3.4

Clinical presentation

There are four cardinal components of symptoms associated with PD: motor symptoms,
cognitive changes, behavioral/neuropsychiatry symptoms, and autonomic nervous system
failures. These can be divided into motor and non-motor symptoms.
1.3.4.1 Motor symptoms
The major motor features of PD are sometime represents by a mnemonic TRAP. It stands
for Tremors, Rigidity, Akinesia (or bradykinesia) and Postural instability. According to
pathological and neuroimaging studies, onset of motor symptoms occurs only after about
50-70% of neurodegeneration of substantia nigra (89,128). Rate of motor symptoms are
highly variable among patients. Bradykinesia is the most characteristic clinical
manifestation of PD that refers to slowness of movement. Patients often describe
bradykinesia as tiredness or weakness and commonly report difficulty from getting up
from a chair and opening packages or containers (129). Rigidity of idiopathic PD referred
to as ‘cogwheel’ phenomenon is when patients experience difficulty to initiate a
movement. At the beginning, it is unilateral but can move to other sides in the later stages
of the disease. Tremors at rest are the most easily recognizable symptom of PD that are
always prominent at the distal part in the extremities and occur at frequency between 4 to
6 Hz. At the late stages of PD usually after onset of other clinical features postural
instability develops due to loss of postural reflexes. Postural instability along with
freezing of gait significantly increases the risk of hip fracture due to sudden fall (130133).
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In addition to classic motor features, other motor symptoms are also observed including
dysarthria, masked facial expression (hypomimia), dysphagia, blurred vision, decrease
eye blink, dystonia and difficulty turning in bed (93).
1.3.4.2 Non-motor symptoms
Along with the motor symptoms of PD, the non-motor symptoms (NMS) are major cause
of disability for PD patients but unfortunately unlike motor symptoms NMS are not well
recognized and undertreated (109,134-136). Recognition and treatment of NMS is an
important and fundamental aspect to consider in order to delivering a comprehensive
healthcare for PD patients. NMS arise with the progression of disease and are diverse
including neuropsychiatric symptom, sleep disorder, autonomic symptom,
gastrointestinal symptom and sensory symptom (Table 1.4). Sometime treatment of PD
leads to development or exacerbation of NMS in PD patients therefore it is important to
recognize, monitor and treat these symptoms (135-138).
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Table 1.4 Non-motor Symptoms of Parkinson’s disease
Neuropsychiatric

Sleep disorders

symptoms
Depression

Restless legs

Autonomic

Gastrointestinal

symptoms

symptoms

Bladder

Dribbling of

disturbances

saliva

Urgency Nocturia
Apathy, anxiety

Periodic limb

Obsessional behavior

movements

Anhedonia

REM behavior

Orthostatic

disorder

hypotension (OH)

Excessive daytime

Sexual

Vomiting

somnolence

dysfunction

Nausea

Vivid dreaming

Erectile

Constipation

impotence

Fecal

Attention deficit

Hallucinations

Sweating

Dysphagia/choki
ng
Reflux

incontinence
Delusions Dementia

Non-REM sleep-

Hypotestosterone

Unsatisfactory

related movement

state

voiding of bowel

disorders Insomnia
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1.3.5

Management of Parkinson’s disease

Currently, there are only symptomatic treatments available with no proven
neuroprotective agents. For earlier stages of disease after diagnosis, it is important to take
time and educate the patient and relative about the condition and its implications. The
decision to start the treatment especially at earlier stages of disease when there is little
functional deficit is difficult. This decision should be made based on the age of the
patient, the consents of the patient, the presence of cognitive impairment, the likelihood
of complications associated with treatment and additional health problems (89,139,140).
The current gold standard regimen for managing symptoms is precursor of Dopamine i.e.
L-3,4- dihydroxyphenylalanine (L-Dopa or levodopa). Levodopa can cross the blood
brain barrier (BBB) easily to enter the central nervous system where it converts into
dopamine in the presence of an enzyme L-aromatic decarboxylase (133). Although LDopa reduced the symptoms of PD and decreased the mortality rate associated with PD,
it is responsible for wide range of side effects due to peripheral conversion into dopamine.
To avoid these side-affects, dopa decarboxylase inhibitors, Carbidopa and Benserazide
are co-administered that cannot cross BBB and only inhibit peripheral dopamine
conversion. However, chronic use of L-dopa is associated with induction of dyskinesia
that is particularly problematic at later stages of disease with loss of large number of
dopaminergic neurons (141).
Another strategy to treat symptoms of PD is the use of dopamine agonists including ergot
derivatives such as bromocriptine, pergolide, cabergoline and lisuride; and non-ergot
derivatives as ropinirole and pramipexole. Dopamine agonists produced fewer of motor
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complication compared with L-dopa but efficacy is much lower when used as monotherapy (142-144).
One more class of drug, the monoamine oxidase B (MAO-B) inhibitors, Selegiline and
Rasagiline, have demonstrated efficacy in PD disease and have potential to use as monotherapy in both early and advanced disease. An N-methyl-D- aspartate (NMDA) receptor
antagonist, amantadine, and anticholinergics such as benztropine have also been proven
efficacious in a small sub-population of PD patients (112,139,143,145). After few years
of consistent and effective response to L-dopa, the effect of a single L-dopa dose in most
patients fluctuates in terms of motor performance leading to wearing-off phenomenon.
Several catechol-O-methyl transferase (COMT) inhibitors and amantadine have been
used in combination with L-dopa for the treatment of dyskinesias and other motor
symptoms (144,146). A surgical procedure called deep brain stimulation has been
reserved for patients who are unresponsive to pharmacological treatment and have a high
degree of motor fluctuation and dyskinesias (147).
1.3.6

Yeast Model of Parkinson’s disease

Saccharomyces cerevisiae is a compatible cell model to understand the molecular
mechanisms of several human diseases including PD, for which many α-syn toxicity
models have been developed (148,149). This unicellular eukaryote is a well-suited model
for studying the disease related phenotypes, for instance, stress response, mitochondrial
and vesicular trafficking defects as well as oxidative stress response. In addition, this
simple genetic model has been extensively used for large-scale screening of drugs and
genes to uncover the underlying mechanism of disease (17,148-157). In this study we
used a budding yeast (Saccharomyces cerevisiae) model of PD that evaluates α-syn
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misfolding, aggregation, and toxicity. In this model, at relatively low concentration of αsyn localizes to membrane and is not toxic to cells. When two gene copies of α-syn are
expressed, an increase in the concentration of α-syn forms prominent intracellular
cytoplasmic inclusions or foci that are associated with toxicity to the cells. This
Saccharomyces cerevisiae model throws light on α-syn's role in PD pathogenesis (158).
This simple experimental model is very useful to dissect and understand the biochemical
mechanisms of many diseases, as there is high mechanistic similarity of many
physiological processes with human cells.
1.4

Prion disease

Prions are self-replicating proteins that are responsible for fatal neurodegenerative
disorder known as prion diseases or transmissible spongiform encephalopathies affecting
multiple mammalian species such as Kuru, bovine spongiform encephalopathy (BSE) and
scrapie, in human, cattle and sheep respectively (159-161). They are generally considered
a transmissible disease within and between different mammalian species as transfer of
brain extracts from affected persons into host species can spread the disease (162-164).
Transmission among humans could occur during surgical procedures or pituitary
hormone treatment, for example, 450 cases of iatrogenic Creutzfeldt–Jakob disease (iCJD)
have been reported during such treatments. Blood donors with undetected subclinical
symptoms could be a reason for variant CJD (vCJD) in humans. Cannibalistic rituals in
Papua New Guinea were also historically linked with transmission of Kuru (165-173).
Normal cellular prion protein (PrPC) is a 253 amino acid long protein encoded by a gene
PRNP on chromosome 20 mutations of which is associated to genetic prion disease. The
scrapie prion protein (PrPSc), is a pathological form of prion protein present in the brain
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tissue of patients with transmissible spongiform encephalopathy (TSE). PrPSc differs with
normal cellular prion protein (PrPC) by translational modification and is formed by
recruiting PrPC conformers, which later perpetuate into larger aggregates that trigger
neurotoxic signals (162,163,174-177). These are the characteristics of typical spongiform
that are seen in the patient’s brain. A list of major prion diseases is provided in the table
1.5.
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Table 1.3 List of prion diseases.
Disease

Natural host

Rout of transmission or disease-induction

species

mechanism

Sporadic CJD

Humans

Unknown

Iatrogenic CJD

Humans

Accidental medical exposure to CJDcontaminated tissues, hormones or blood
derivatives

Familial CJD

Humans

Genetic (germline PRNP mutations)

Variant CJD

Humans

Genetic (germline PRNP mutations)

Kuru

Humans

Ritualistic cannibalism

Fatal familial

Humans

Genetic (germline PRNP mutations)

Humans

Unknown

Humans

Genetic (germline PRNP mutations)

Scrapie

Sheep and goat

Horizontal and possibly vertical

Atypical

Sheep and goat

Unknown

insomnia
Sporadic fatal
insomnia
Gerstmann–
Sträussler–
Scheinker
syndrome

scrapie
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Table 1.5 continued

Chronic

Mule deer, white-

wasting disease

tailed deer, Rocky

Horizontal and possibly vertical

Mountain elk and
moose
BSE

Cattle

Ingestion of BSE-contaminated food

Atypical BSE

Cattle

Unknown

Feline

Zoological and

Ingestion of BSE-contaminated food

spongiform

domestic felids

encephalopathy
Transmissible

Farmed mink

Ingestion of BSE-contaminated food

Spongiform

Zoological

Ingestion of BSE-contaminated food

encephalopathy

ungulates and

of zoo animals

bovids

mink
encephalopathy

BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt–Jakob disease; PRNP, gene encoding prion
protein; PrPC, cellular prion protein
Adopted from Adriano Aguzzi et. al. (2013) Nature Reviews Immunology 13, 888–902 (178)
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Like other neurodegeneration-associated amyloid proteins, PrPSc protein is rich in β-sheet
content and is protease resistant, thus it not easily degraded by cellular enzymes. These
protease resistant amyloids of PrPSc are then deposited in the brain tissue during
progression of the disease. Prion aggregation can occur both intracellularly and
extracellularly. Specific prion antibodies can detect amyloid plaques caused by prion
protein that appear similar to those of AD (162,164,179). On the other hand, how prions
destroy the neurons in CNS is still enigmatic. Numerous studies investigating the
mechanism of prion aggregate formation and propagation are performed in yeast and
many of the findings from these studies are applicable to human prion diseases.
1.4.1

Prions in yeast

Although no homologue of PrPC exists in yeast, many proteins have been discovered that
are present in different conformations including normal soluble or amyloid aggregated
forms. Different conformations of the same protein are linked with distinct phenotypes in
yeast. In yeast, prions act as epigenetic cytoplasmic elements that provide phenotypic
diversity in a heritable manner that operates at the level of protein conformation without
the need of nucleotide sequences (180-185).
Reed Wickner in 1994 proposed that the previously known yeast non-Mendelian
heritable elements [URE3] and [PSI+] are prions of Ure2 and Sup35 proteins
respectively(186,187). Prion are often linked with a loss of function phenotype in yeast.
Sup35 is a translational termination factor that loses its function in a way that translation
termination efficiency is compromised in the presence of the prion form of Sup35
(98,188-191). Similarly, the normal function of Ure2 is to regulate nitrogen catabolism,
preventing uptake of an intermediate, ureidosuccinate (USA), involved in the uracil
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biosynthesis pathway. Thus the [URE3] prion form of Ure2, loses its normal function in
ura2 mutant cells and can grow on –Ura media by taking up USA (186,188,192-196).
Prion traits are dominant since aggregated forms of a prion can recruit the identical
soluble prion protein and convert it into the prion conformation. [PSI+] prion exists in
different variants similar to the observation in mammals that are genetically identical
showed different characteristics of prion in isolates of disease that can be stably
reproduced (164,197). Variation in the ratio of aggregated vs. soluble Sup35 protein is
linked with different variants of [PSI+] prion, known as weak or strong forms of the prion.
[PSI+] prion variants lead to different degree of loss of function for example, in the
presence of ade1-14 nonsense stop codon, strong variants will cause greater degrees of
translational read-through compared with weak variants resulting in accumulation of
characteristic red pigments indicating the absence of ADE1 (198-202).
1.4.2

Structural organization

1.4.2.1 Prion forming domain
Most of the yeast prion proteins contain a region that is required for the formation and
propagation of the prion without requiring the remaining portions of the protein (203).
Such regions are known as prion-forming domains or PrDs. Sup35 PrD or Sup35N
domain is also involved in other cellular functions other than its role in prion formation
(204). A middle domain (Sup35M) links PrD to the C-terminal domain. Sup35M domain
is composed of highly charged amino acids residues that help to maintain prion
aggregation possibly by interaction with HSPs (205). Yeast PrDs are Q and N rich
domain, that when artificially recombined to different proteins may confer a prion state.
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Sup35 prion forming domain (PrD) can be divided into two segments, the QNR stretch
and the OPR element based on the observation that the fragment of PrD required for
protein aggregation is shorter than segments needed for efficient propagation of prion
(Figure 1.2) (161,180,206,207).
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685
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PrD
Non-polar (%)

30.9
Uncharged, polar (%) 65.0
Charged, polar (%) 4.1
B
1

31.5

48.6

26.2
42.3

22.7
28.7

QNR

OPR
40

97

Figure 1.2. Sup35 structural domains organization.
The Sup35 protein is divided into three domains based on the position of Met residues.
The first domain N (amino-terminal) Met1 to residue 123, the M (middle) domain
between Met 124 and residue 253, and C (craboxy-terminal) region from Met 254 to
residue 685. The N-terminal domain is known as the PrD and is enriched in uncharged
polar residues that are required for the formation of prions. The C-terminal domain is an
essential region that functions as translation termination release factor. The minimal PrD
domain consists of 1-97 amino acids that are composed of two distinct regions within it;
QN rich region (QNR) and the oligopeptide repeat region (OPR).
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1.4.2.2 De novo prion formation
The frequency of prion de novo appearance is considerably low unless prions or their
PrDs are transiently overexpressed resulting in the dramatic increase in the rate of prion
formation by up to 3000-fold. Interestingly, overexpression of just the PrD is more
efficient than transient overexpression of full-length protein (181,191,201,208). Still
elevated levels of PrD as such, is not sufficient for prion formation and requires the
presence of another QN rich prion, [PIN+] in aggregated state, for de novo prion
formation (209). [PIN+] is a prion form of the Rnq1 protein that was first discovered as a
non-Mendelian factor with prion like properties (181,201,208,210-212). The amino acid
composition of Rnq1 is similar to the PrD of Sup35 and it is proposed that [PIN+] acts as
an initial nucleus for de novo Sup35 prion aggregation formation. The de novo [PSI+]
prion formation in the presence of [PIN+] by transient overexpression of Sup35 or its PrD
is a multi-step process initiated by accumulation of misfolded protein in insoluble protein
deposits (IPODs) quality control (213,214). Fusing of Sup35 to GFP, allows the
visualization of formation of in vivo prion behavior, in which the fluorescent signal
appears as a ring-like and long filamentous structures at the periphery of cells. These
rings later collapse together to form internalized smaller rings that enclose the vacuoles.
After cell division the daughter cells appeared with dot-like foci of [PSI+] (213).
Aside from the presence of [PIN+], several other cellular components have been reported
to control de novo prion formation and propagation. Most of these components are
involved in stress response pathways such as chaperones, ubiquitin-proteasome system,
intracellular trafficking networks and members of actin cytoskeleton (215-221).
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1.4.3

Effect of heat shock proteins on prion propagation

Although prion proteins require no cofactor to generate and propagate amyloid
aggregation in vitro, de novo prion propagation is modulated by chaperones such as
Hsp104, Hsp70, Hsp40 and sHSPs such as Hsp26 and Hsp42 (36,39,53,222-225).
Hsp104 is a member of the AAA ATPase chaperone family with homohexameric
structure and required for prion propagation in vivo. Hsp104 and its bacterial homolog,
ClpB, possess potent disaggregase activity against stress damage protein aggregates (226228). Deletion or overexpression of Hsp104 eliminates [PSI+] prion, thus an intermediate
level of Hsp104 is required for prion propagation (222,223,229,230). It was proposed that
Hsp104 generates smaller seeds by promoting fragmentation of larger prion fibers that
initiate propagation. It was also hypothesized that elevated Hsp104 cures [PSI+] prion by
monomerization of large aggregates but evidence for this hypothesis are based on the
indirect observation that overexpression of Sup35, leading to an increase in aggregate
size, partially compromises the curing effect of excess Hsp104 (231). Another model
proposes that elevated levels of Hsp104 cures [PSI+] by dissolution of the prion seeds,
the evidence for this model came from observation that Hsp104 overexpression induces a
diffuse localization signal for Sup35 tagged with GFP and a large fraction of soluble
Sup35 was observed in cell lysate (226,232,233). Recent studies also suggest that
dissolution of prion seed might be due to the trimming activity of Hsp104 in which
Sup35 dissociates from the seed terminus, hence that reducing its size without generating
new seeds. Trimming activity of Hsp104 is still present even when severing activity is
inhibited by treatment of guanidine (223). The effects of Hsp104 on prion curing are
strongly influenced by other chaperones or co-chaperones including the Hsp70 chaperone
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system consisting of Ssa and its co-chaperones, Ydj1 or Sis1 and the Sse proteins
(38,40,208,234,235). The Hsp70 co-chaperone system has an essential role at the initial
steps of the disaggregation processes possibly by facilitating Hsp104 to recognize and
extract single polypeptide from aggregates at later stages (225). Remarkably, different
families of Hsp70 i.e. Ssa and Ssb shows contrary effects on [PSI+] prion. Ssb
overexpression enhances curing of [PSI+] prion by Hsp104 while Ssa protects [PSI+]
from curing by Hsp104. Ssa overexpression and Ssb deletion also increase de novo [PSI+]
prion formation. At the molecular level Ssa interacts with Sup35 and overexpression of
Ssa increases the polymer size of Sup35 (225,236-239). Altered expression of Hsp40
(Sis1 or Ydj1) by mutation, transient depletion or internal deletion, also influences the
dynamics of [PSI+] prion propagation. Sis1 overexpression promotes [PSI+] prion curing
by Hsp104. It is also proposed that Sis1 is responsible for recruiting Ssa and Hsp104 to
prion aggregates. Unlike Sis1, Ydj1 is non-essential and is shown to cure weak variants
of [PSI+] prion, but only when Ssa1 is also co-expressed (225,234). The exact mechanism
of action of Hsp70 and Hsp40 family members in prion propagation is still under
investigation but it is clear that they collaborate with Hsp104 and play crucial roles in
prion propagation. Deletion of co-chaperones of Hsp70/90 such as Sti1 or Cpr7, also
inhibit [PSI+] curing by Hsp104 over-expression (40).
In addition to Hsp104 and its assistant chaperones, sHSPs such as Hsp31, Hsp26 and
Hsp42 also play a role in disaggregation of misfolded proteins in yeast (53,240-242).
These proteins are highly expressed under moderate stress and during late growth phase
for transition to stationary phase. Hsp42 and Hsp26 work synergistically to inhibit prion
formation and potentiate dissolution of Sup35 prion aggregates by distinct mechanisms
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(53). Furthermore, Hsp26 or Hsp42 collaborate with Hsp70 and or Hsp104 to reduce the
SDS-resistant polyglutamine aggregation (243). The diverse effects of chaperones on
prion propagation is summarized in table 1.6.
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Table 1.6 Effect of chaperones on [PSI+] prion curing
Effect on [PSI+]

Chaperone
Family

Protein/Subfamily

Excess

Inactivation/deletion

Hsp100

Hsp104

Cures

Cures

Hsp70

Ssa (1-4)

Destabilizes

Destabilizes

Protects from
elevated Hsp104
Ssb (1-2)

Destabilizes

Protects from

Helps cure by

elevated Hsp104

elevated Hsp104
Hsp40

Sis1

Helps cure by

Antagonizes

elevated Hsp104

Hsp90

Ydj1

ND

Does not cure

Hsp82

No effect

Protects from
elevated Hsp104

SHSPs

Hsp42, Hsp26

Cures

ND

Co-70/90

Sti1

ND

Protects from
elevated Hsp104

Cpr7

ND

Same as above
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1.4.4

Prion associated toxicity

The unusual conformations of normal proteins into self-assembly leads to formation of
amyloid aggregates that has been implicated in both the acquisition of new traits and in
the emergence and progression of disease. In yeast, the presence of [PSI+] prion itself is
not toxic but overexpression of Sup35 or its PrD in such a strain is lethal (215,221,244).
It is proposed that toxicity is caused by recruitment of essential protein(s) including
another translational release factor Sup45 (245-247). Also, the combination of [PSI+]
prion together with tRNA suppressor induces the stress response (248,249). Some
variants of [PSI+] that are toxic can be rescued by overexpression of Sup35 derivative
that lack PrD and cannot be recruited by aggregates (250). Specific mutations in Hsp104
leads to [PSI+]-dependent cytotoxicity in yeast cells (251). Some variants of [PSI+]
prions that are not toxic per se may become toxic when combined with other factors such
as a polyQ stretch from human Huntingtin protein in [PIN+] or [PSI+] strains that are
otherwise non-toxic (245,252).
1.5

DJ-1/ThiJ/Pfp1 superfamily

The members of DJ-1 superfamily are large number of proteins with conserved threedimensional structure distributed across eukaryotes and prokaryotes (253-259). Members
of the family such as DJ-1, hchA and Hsp31 possess similar primary, secondary and
tertiary structures with the difference in the presence of main domains (P and A domains).
In addition, they also differ in the formation of homo-dimerization such as DJ-1
monomer interacts through α-helices while Hsp31 dimerization is stabilizes by β-sheets.
Another prominent feature of these family members is the presence of a conserved
cysteine catalytic triad (Figure 1.3).
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A

Yeast Hsp31

B

Yeast Hsp31 homodimer

C

Human DJ-1 homodimer

Figure 1.3. Ribbon structure of Hsp31 and dimerization.
(A) Crystal structure of yeast Hsp31 monomer depicting catalytic triad. The core is in
color blue and cap is in red. The catalytic triad (Cys138, His139, and Glu170) are shown
as sticks in yellow color (Adopted from M Graille et. al. 2004 with permission) (B)
Ribbon structure of homodimerization of yeast Hsp31. (C) Homodimer of human DJ-1
protein. (Adopted from W Ying et. al. (2007) Open access Journal PLoS computational
biology.

40
Despite highly conserved structure, members of this family are diverse in functions
including catalases, glyoxalases, proteases, transcriptional regulators and chaperones.
However, they are all involved in cellular stress response (158,260-266). Special
attention has been drawn to this family because of human member of the family, DJ-1,
that has a well-characterized involvement in two major diseases, cancer and PD (267270). A large number of studies have investigated the cellular function of DJ-1 and its
role in modulating disease pathogenesis. Other members of the family include E.coli
Hsp31, archeal Pyrococcus horikoshii proteins (PH1704, YajL and Yhbo) and Hsp31 in
the yeast Saccharomyces cerevisiae that has three other paralogs (Hsp32-34)
(255,258,271-274).
1.5.1

Human DJ-1

Human DJ-1 is a small protein of 189 amino acids that is expressed ubiquitously in
several tissues of body including brain and is mainly localized in the cytoplasm but also
present in mitochondria and the nucleus. It was first identified as an oncogene that is
elevated in several types of cancers such as leukemia, breast cancer, primary lung cancer,
prostate cancer, cervical cancer and pancreatic cancer (270,275-279). The oncogenic
potential of DJ-1 is thought to be related to its interaction with tumor suppressor
phosphate and tension homolog (PTEN) in the PI3K-Akt pathway that regulates cell
proliferation and transformation (280). Later studies showed its implication in
neurodegenerative disease such as mutations in the gene PARK7 cause early onset of
autosomal recessive PD (267,281-285). Mutations in DJ-1 that destabilize
homodimerization show the quaternary structure is critical for cellular function. The
conserved cysteine residue, C106, is also important to regulate cellular function and
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localization of DJ-1. C106 is highly susceptible to oxidation and mutations affect its
function, oligomerization and localization(286-289). Interestingly, oxidatively damaged
proteins are found in the brains of patients with idiopathic PD, AD and HD. Like other
members of the family DJ-1 also function as methylglyoxalase and deglycase of glycated
proteins in the cell (290-292). In addition, DJ-1 positively regulates the antioxidant
transcription factor, erythroid 2-related factor 2 (Nrf2) (293). The multiple cellular roles
of DJ-1 and the different biochemical activity contributions to its overall role are under
investigation but compelling evidence indicates that it is a multifunctional chaperone that
protects cells from oxidative and associated stress similar to the yeast Hsp31 protein.
Interestingly, our understanding of DJ-1 function has been more advanced than the yeast
counterpart but new studies including ours are elucidating the function of yeast Hsp31
that will be applicable to DJ-1.
1.5.2

The yeast Hsp31 mini family

The yeast Saccharomyces cerevisiae Hsp31 mini-family consists of four paralogs, HSP31
(YDR533C), HSP32 (YMR322C), HSP33 (YOR391C), and HSP34 (YPL280W) (272).
Among the four members, HSP31 is the most divergent and is proposed to have been
duplicated during yeast evolution resulting in the paralogous genes. After resolving the
crystal structure of yeast Hsp31, the name was given because of structural similarity with
E. coli Hsp31. Hsp32, Hsp33 and Hsp34 share over 90% sequence homology. While,
Hsp31 is only about 70% similar to other members (271,272).
1.6

Role of Hsp31 in cellular stress response

Consistent with the main role of cellular stress response, Hsp31 expression is strongly
induced during late phases of growth and required for survival under conditions of
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nutrient limitation (294). Hsp31 expression is also induced when yeast cells are treated
with H2O2 to produce oxidative stress and this up-regulation of Hsp31 is under the
control of stress responsive transcription factor, Yap1 (158,295). In addition, Hsp31
possesses robust glutathione independent glyoxalase activity that converts the toxic
metabolite, methylglyoxal (MGO), into D-lactate (158,260,261). The catalytic triad CysHis-Glu of Hsp31 is vital for this enzymatic activity and critical for suppressing the
elevated level of ROS by MGO (158,260). An overall view has emerged indicating
Hsp31 has important metabolic and regulatory roles in cytoprotective pathways (296).
In addition to the enzyme activity, we also demonstrated that Hsp31 has broad chaperone
activity in several classic protein aggregation assays indicating its ability to manage
misfolded proteins that initiate proteotoxic stress in the cell. We also demonstrated that
the yeast-purified protein was more active in preventing aggregation of several substrate
proteins including α-syn (158). The increased activity may be due to the difference in the
affinity tags used but may be a result of posttranslational modification(s) that occur in the
cell. Several reports have indicated that post-translational modifications or differing
levels of oxidation of the cysteine residue can alter activity of DJ-1 (297,298). In addition,
we showed that yeast Hsp31 is more active in preventing protein aggregation compared
to DJ-1. Interestingly, it has also been observed that Hsp31 rescues α-syn and huntingtin
toxicity to a greater extent than DJ-1 in vivo using yeast as a model system (106,299).
These results raise the intriguing possibility that Hsp31 is constitutively active whereas
DJ-1 must undergo an activation event to increase its activity although more studies must
be performed to confirm the mechanism for these differences.
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Hsp31 inhibits the formation of aggregates of a wide range of proteins including insulin,
citrate synthase, α-syn and the Sup35 prion (158). The recombinant soluble α-syn and
Sup35 proteins can readily polymerize into amyloidogenic fibrils in vitro (300). Hsp31
inhibits protein aggregation formation in vitro and foci formation of GFP-tagged proteins
in vivo. In addition, over-expression of Hsp31 can rescue cells from toxicity associated
with overexpression of α-syn. The rescue phenotype could be mediated by several
different mechanisms including Hsp31’s methylglyoxalase or deglycation activities.
However, a Hsp31 mutant deficient in methylglyoxalase activity is still very active in
preventing α-syn in vitro aggregation and prevention of toxicity from overexpressed αsyn (158). Another possible rescue mechanism could be the autophagy pathway,
particularly because deletion of Hsp31 impairs autophagy under carbon starvation
conditions (294). Autophagy does alleviate toxicity from α-syn overexpression because
we show a synthetic lethal relationship between α-syn overexpression and deletion of
ATG8. However, we demonstrated that overexpression of Hsp31 in the atg8Δ strain can
rescue α-syn-mediated toxicity (158). These data show that despite the multitasking
abilities and roles of Hsp31, the chaperone activity appears to have the ability to prevent
α-syn toxicity independent of other activities. In support of our finding, another study
found the autophagy pathway was not crucial in preventing the Hsp31 chaperone activity
against a cytoplasmic aggregation prone protein. The same study also demonstrated that
Hsp31 chaperone activity overlaps with the Ubr-dependent degradation pathway but is
independent of its function in the oxidative stress response (262). Further exploration of
this model would need to utilize mutants that abrogate chaperone function without
affecting enzyme activity and other biological functions.
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The typical model of protein aggregation proposes that unfolded monomers as an
initiating event that progresses to unstable oligomeric intermediates, and finally elongates
to larger oligomers. The observed anti-aggregation activity of Hsp31 raises the question
of what stage Hsp31 intervenes in the protein aggregation process. On the bases of our in
vitro studies, Hsp31 likely interacts with early oligomeric intermediates of α-syn and
therefore prevents higher oligomer formation. For example, when soluble α-syn was
mixed with Hsp31, formation of precipitated SDS-resistant oligomers was markedly
reduced. Likewise, the soluble fraction of α-syn, which included SDS-resistant oligomers
in the size range of 25-50 KDa, was almost completely abolished in the presence of
Hsp31 indicating that Hsp31 likely interacts with the monomeric or early oligomers in
preventing the formation of higher order oligomers. We observed similar results with the
in vitro ThioT assay, in which incubating the Hsp31 with α-syn completely prevented the
increase in fluorescence intensity associated with increasing fibril formation again
supporting our model that Hsp31 acts at early stages of protein aggregation (158). Of
particular interest is that DJ-1 has been shown to interact with monomeric and oligomeric
form of α-syn as determined by pull-down assays (106). This same study also showed
that DJ-1 interacts with α-syn in vivo as well. Along with α-syn aggregation formation,
we also demonstrated the inhibitory effect of Hsp31 on the Sup35 prion based on
reduction of aggregates observed in cell lysates. These results support the notion that
Hsp31 acts at the early stages of oligomerization to prevent further protein
oligomerization. Interestingly, we previously showed that the overexpression of Hsp31
reduces the level of Sup35 aggregation but we also show that it is unable to cure prions
from a [PSI+] strain. [PSI+] strains contain Sup35 prion aggregates that can be cured by
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chaperones such as Hsp104, but the lack of curing by Hsp31 suggests that it lacks
disaggregase activity and cannot intervene in an established prion cycle. Moreover, our
study showed no co-localization of Hsp31 and Sup35 aggregates as observed under
fluorescence microscope, rather Hsp31 is occluded from Sup35 prion aggregates,
indicating that Hsp31 acts on its substrates prior to the formation of large aggregates. The
strong chaperone activity of Hsp31 suggests that it may modulate prion aggregates but
might need to cooperate with other chaperones similar to what has been demonstrated
with other small HSPs such as Hsp26 and Hsp42 (53).
1.7

Comparison of Hsp31 paralogs

The paralog genes of the Hsp31 mini-family are located at the subtelomeric region of the
genome in Saccharomyces cerevisiae (272). All the members of Hsp31 family contain
the same Cys-His-Glu catalytic triad as present in the E. coli ortholog but interestingly no
protease activity has been detected so far for Hsp31 or other paralogs. Previously, it was
shown that mutation in the catalytic triad largely abolishes glyoxalase activity, but this
catalytic triad is not required for chaperone activity of Hsp31 (158). These results
indicate that the anti-aggregation activity of Hsp31 is not under the influence of its
enzymatic activity rather, it has a direct chaperone activity against misfolded proteins.
Intriguingly, all the paralogs of the Hsp31 minifamily possess comparable activity against
α-syn aggregation and toxicity when they are overexpressed from the GAL promoter
(106). Furthermore, the chaperone activity of Hsp31, Hsp32 and Hsp33 against a
cytoplasmic aggregation-prone protein is independent of their role in oxidative stress
response and the vacuolar degradation pathway (262). However, unlike Hsp31, the other
paralogs possess very little methylglyoxalase activity and are unable to protect the cells
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from glyoxal toxicity (260). These results again support the notion that anti-aggregation
activity of Hsp31 mini-family is independent of its enzymatic activity. In addition, the
lack of methylglyoxalase activity in the paralogs is evidence that the paralogs are
diverging but additional studies dissecting the roles within this paralog group are needed
to further uncover these diverging functions. The Hsp31 protein family is broadly spread
across fungal species with varying levels of paralog duplications and additional evidence
of divergence including differences in localization in the Schizosaccharomyces pombe
Hsp31 family members (264). A functional comparison of Hsp31 and its paralogs are
summarized in Table 1.7 highlighting the similarities and differences among these
proteins.
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Table 1.7 Summary of Hsp31 and paralog functions
Function/Attribute

Hsp31

Hsp32

Hsp33

Hsp34

Catalytic triad

Yes

Yes

Yes

Yes

Chromosome Position

Interstitial

Telomeric

Telomeric

Telomeric

Sequence homology

~70%

>90%

>90%

>90%

Chaperone activity

+++

+++

+++

+++

Methylglyoxalase

+++

+/-

+/-

+/-

Deglycase

+++

ND

ND

ND

Role in Autophagy

+

+

+

+

Peak mRNA level

Early SP

DS

Early SP

ND

Stress granule and P body

Yes

Yes

ND

ND

Yes

ND

ND

ND

localization
Mitochondrial localization
ND = Not determined
SP = Stationary Phase
DS = Diauxic shif
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1.8

Hsp31 role in redox homeostasis

Oxidative stress occurs when intra-cellular ROS overwhelms the anti-oxidative defense
system in the cell present during normal aerobic metabolism or by exposure to external
radical generating agents. ROS triggers damage to macromolecules in the form of
oxidative modifications and misfolding of proteins, associated with the development of
diseases and pathological conditions such as PD and prions (62,184,301,302). Hsp31 has
an important role in maintenance of redox homeostasis in yeast under oxidative stress
generated by MGO or H2O2 (260,303). Like many other heat-shock genes HSP26, HSP12,
HSP82, and SSA3, expression of HSP31 is strongly induced at diauxic shift when the
cells are stressed by nutrient limitation and by accumulation of oxidative metabolites
(158,294,303). Others and we also reported an elevated level of Hsp31 under oxidative
stress when cells were treated with H2O2 (158,303). Similarly, Hsp31 also plays a role in
the survival of cells during stationary phase and protects cells from oxidative stress
caused by MGO and H2O2 accumulation (158,303). In addition, we demonstrated that
Hsp31 expression was induced under proteotoxic stress such as overexpression of α-syn
(158). In support of the role of Hsp31 in managing this proteotoxic stress, we found that
deletion of HSP31 synergizes with α-syn expression to increasing toxicity. We reported
an increase in ROS level in the hsp31Δ strain that correlates with increased toxicity by αsyn expression compared to wild type (WT) strain, indicating that the presence of Hsp31
is important in reducing ROS to basal levels. In agreement with our study,
overexpression of Hsp31 robustly suppresses both cytosolic and mitochondrial ROS
levels instigated by MGO and H2O2 and therefore provide cytoprotection (158,260). In
addition, Hsp31 localizes to mitochondria and preserves mitochondrial integrity by
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redistributing glutathione to the cytoplasm under oxidative stress (260). Another study
examined the deglycase activity of Hsp31 and showed that it may efficiently deglycate
proteins with glycated Cys, Arg and Lys amino acid residues (265). Taken together, these
results suggest that Hsp31 is an integral part of the heat shock protein system and plays a
vital role in maintaining cellular homeostasis.
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CHAPTER 2. HSP31 IS A STRESS-RESPONSE CHAPERONE THAT INTERVENES
IN THE PROTEIN MISFOLDING PROCESS

This chapter contains parts of following publications:
Chia-Jui Tsai*, Kiran Aslam*, Holli M Drendel, Josephat M Asiago, Kourtney M
Goode, Lake N Paul, Jean-Christophe Rochet, Tony R Hazbun Hsp31 is a StressResponse Chaperone that Intervenes in the Protein Misfolding Process. The Journal of
biological chemistry, 290(41):24816-34, 2015
Kiran Aslam, Tony Hazbun Hsp31, a member of the DJ-1 superfamily, is a multitasking
stress responder with chaperone activity. Prion Apr 2016
2.1

Abstract

The Saccharomyces cerevisiae Hsp31 is a homodimeric protein that is highly induced
under stressful situations and involved in diauxic shift reprogramming. It is a protein with
multifunctional roles including functions as a chaperone, methylglyoxalase, deglycase
and is involved in the autophagy pathway. Hsp31 is homolog of human DJ-1 that has
implications in the pathophysiology of PD. We verified that Hsp31 are highly induced
under oxidative stress. Furthermore, we showed its induction under proteotoxic stress
condition. We confirmed that Hsp31 is a robust methylglyoxalase that is more potent in
activity than its human homolog DJ-1. We demonstrated that Hsp31 chaperone activity to
protect the cells from α-syn toxicity is not under the influence of its enzymatic activity or
autophagy pathway. We also showed that Hsp31 inhibit Sup35 PrD aggregations as
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observed under fluorescence microscopy and flow cytometry. In addition, we provide
evidence that Hsp31 act early in the process of protein aggregation because Hsp31 does
not co-localize with larger Sup35 prion aggregates. These results establish that Hsp31
molecular chaperone activity is self-sufficient to protect the cells from stress conditions
without requiring its enzymatic activities.
2.2

Introduction

Yeast Hsp31 is encoded in the Saccharomyces cerevisiae genome and has drawn
attention after its structure was solved in 2003 indicating that it has structural similarity
with an evolutionarily conserved protein family the DJ-1/PfpI (ThiJ/PfpI) protein family
that includes human DJ-1 and E. coli Hsp31 proteins (271,272). The DJ-1/PfpI protein
family members including human DJ-1 and E. coli Hsp31 are moderately characterized
for their biological functions and role in pathologies but have many unanswered
questions with regards to their multifunctional roles and biochemical activities. Most
studies indicate an important role in response to stressed biological processes (303).
Mutated forms of DJ-1 are involved in early onset PD and DJ-1 is implicated to function
as a chaperone in response to oxidative stress by preventing α-syn fibrillation, a process
involved in PD pathogenesis (304). E. coli Hsp31 is a stress-inducible molecular
chaperone that plays an important role in protein misfolding and helps survival under
acidic stress (305). Initial characterization the yeast Hsp31 function showed that deletion
of HSP31 gene sensitized cells to ROS, suggesting a role for Hsp31 in protecting cells
against oxidative stress (303). Another study showed that yeast Hsp31 is important in
diauxic-shift where its expression is strongly induced and it has a survival role in
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stationary phase of growth. In addition, deletion of HSP31 leads to impaired autophagy
under carbon starvation (294).
Furthermore, DJ-1 family proteins including human DJ-1, E. coli Hsp31 and yeast Hsp31
have been characterized as methylglyoxalases that detoxify by converting MGO into Dlactate independent of GSH (261,264,290). MGO is a toxic metabolite that is mainly
produced as a byproduct of glycolysis. MGO is highly reactive with various amino acids
in proteins, nucleic acids and lipids to yield toxic AGE linked to several diseases. Cells
mainly catabolize MGO by two major enzymes including glutathione dependent GLO I
and GLO II (306,307). DJ-1 and its homologue proteins are characterized as GLO III that
do not require GSH as co-factor to convert MGO into D-lactate. Another study examined
the deglycase activity of DJ-1 and Hsp31 by showing that they efficiently deglycate
proteins with glycated Cys, Arg and Lys amino acid residues (265,292). Investigation of
the yeast Hsp31 is an excellent model to delineate and investigate the specific
biochemical activities of these proteins.
Previously in our lab, it was shown that Hsp31 protect cells against α-syn toxicity
associated with the formation of α-syn foci in a yeast model of PD. It also has been
shown that Hsp31 possesses a chaperone-like response against α-syn aggregation as
observed by an in vitro fibrillization assay as well as insulin and citrate synthase
aggregation assays (158). In the present study, we demonstrate that the protective effect
of Hsp31 against α-syn toxicity in yeast cells is independent of its methylglyoxalase
activity. DJ-1 and Hsp31 possess a conserved catalytic triad Glu-Cys-His, the first two
amino acids of this triad are important for GLOIII activity in DJ-1 (290). Here we tested
a mutation in Hsp31 C138D for methylglyoxalse activity and its activity against α-syn
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toxicity in yeast cells. We also observed the role of Hsp31 in maintaining redox
homeostasis by using an α-syn model of toxicity. In addition, we investigated the effect
of Hsp31 on Sup35 prion aggregation considering that it is potentially a natural substrate
in yeast. Together these findings reinforce the concept that studying the function of
Hsp31 in the context of stress conditions in a yeast model provides new insight about its
functions and it is likely applicable to higher eukaryotes.
2.3
2.3.1

Results

Hsp31 is an integral part of the yeast cellular stress response

Several studies have shown that environmental stresses, such as oxidative stress and
elevated temperature, increased the expression of HSPs. A recent study showed increased
Hsp31 expression upon treatment with H2O2 and another study demonstrated an
increased HSP31 mRNA levels during the diauxic shift growth phase and stationary
phase (294,303). However, the Hsp31 protein level was not characterized under these
conditions. We integrated a 9myc epitope at the C-terminus of the HSP31 genomic locus
to generate a yeast strain that can be used to quantify endogenous protein expression. To
assess whether Hsp31 expression increases under stress conditions, we treated cells with
H2O2 and observed an increased protein expression within an hour of exposure. This was
consistent with previous studies in which increased expression of Hsp31 was observed in
response to a ROS inducing agent. We also examined the expression profile of Hsp31
under proteotoxic stress by overexpressing α-syn and the results indicated that increased
expression of α-syn decreases cell viability, and concomitantly increases the expression
of Hsp31 compared to a strain not expressing α-syn. Our data demonstrate that Hsp31
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expression is rapidly elevated at the protein level in the event of stress associated with
oxidative stress or proteotoxicity (Figure 2.1).
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Figure 2.1 Expression of Hsp31 increases under stress.
(A) H2O2 treatment increases the expression of Hsp31. The Hsp31- 9myc strain was
exposed to 1 mM H2O2 treatment for 30 min and 60 min and increased Hsp31
expression was determined by immunoblot. Samples were normalized to OD600 for
cellular density and β-actin was used as a loading control. This data is representative of
three independent experiments. (B) Quantification of Hsp31 expression with or without 1
mM H2O2 treatment obtained by densitometric analysis and normalized with β-actin
western blot. (n=3, ***p< 0.0001 by two way ANOVA test). (C) Hsp31-9myc expression
increased in the presence of induced expression of GAL-α-syn. The immunoblot was
probed with anti-myc and anti-β-actin antibodies.
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The expression of α-syn has been linked to an increase in the level of ROS in yeast. The
in vivo suppression of α-syn foci by Hsp31 and increased toxicity of one copy α-syn in
the hsp31Δ strain prompted us to investigate the level of ROS in these different genetic
contexts. We found that wild-type yeast did not have detectable superoxide radicals when
treated with dihydroethidium (DHE) using microscopy and a fluorescence level of 0.5
A.U. by flow cytometry. ROS levels were detectable in a fraction of cells in the hsp31Δ
strain (6 A.U.) indicating that the presence of Hsp31 in the cell can decrease ROS levels
of normal cells not expressing α-syn. The remaining strains had increased ROS levels in
the following order: α-syn-YFP strain (23 A.U), α-syn-YFP hsp31Δ (41 A.U), α-syn-YFP
α-syn-CFP (64 A.U) and α-syn-YFP α-syn-CFP hsp31Δ (133 A.U). The latter three
strains with the most ROS levels exhibit reduced viability when α-syn is expressed and
formed increase foci demonstrating a correlation between these phenotypes (Figure 2.2).
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Figure 2.2. Hsp31 decreases the ROS generated by α-syn.
(A) Superoxide ions increase when HSP31 is deleted and when α-syn is expressed. In
vivo presence of superoxide ions is detected by treatment with DHE and visualization by
fluorescence microscopy. Representative fields of view are presented. (B) Quantification
of superoxide ion increase in hsp31Δ and GAL-α-syn expressing strains. Flow cytometry
was performed on three biological replicates. n=3 **** P ≤ 0.0001 based on the one-way
ANOVA with multiple comparison t-test. Error bars = 1 SD.
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2.3.2 Hsp31 methylglyoxalase activity is not required for rescue of α-syn-mediated
toxicity
Recent studies have shown that DJ-1 and Hsp31 are methylglyoxalases that convert
MGO into D-lactate in a single step independent of GSH. Hsp31, like other members of
the DJ-1 superfamily, possesses the conserved Glu-Cys-His catalytic triad. The first two
residues of this triad are critical for MGO activity of DJ-1 as well as Hsp31 in S. pombe
(260,261). We determined the methylglyoxalase activity for recombinant Hsp31 (purified
from E. coli with the GST tag removed on the C-terminus) and a catalytic triad mutant,
Hsp31 C138D, using a commercially available D-lactate assay kit. As expected, Hsp31
could convert MGO into D-lactate with a calculated specific activity of 28.4
µmol/min/mg enzyme (using a saturating substrate concentration of MGO at 6 mM).
These enzymatic parameters indicate a more efficient enzyme activity than the previously
reported Hsp31 specific activity of 10.5 D-lactate µmol/min/mg. Interestingly, the Hsp31
purified directly from a yeast expression system, the GAL promoter induced movable
ORF tag system (MORF), had increased enzymatic activity compared to Hsp31 purified
from recombinant E. coli. We also showed that Hsp31 is a more potent methylglyoxalase
compared to DJ-1, this observation is consistent with several other studies (260,261).
Enzymatic parameters were calculated by measuring the time dependent production of Dlactate with varying substrate concentrations and fitting to a Michaelis-Menten kinetics
model resulting in a Vmax of 0.0356 µmoles D-lactic acid/min (Standard error=0.0016)
and Km was 247.4 µM (standard error=31.5). Specific activity for the mutant could not
be determined because low levels of D-lactate were produced despite using five times the
amount of protein (detection limit of 0.4 µmol/min/mg). The reaction products of these
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assays were examined by GC-MS and a peak identical to the lactic acid standard (6.09
min elution time) was identified, confirming the production of lactic acid by Hsp31.
Lactic acid was undetectable by GC-MS analysis in the Hsp31 C138D sample (Figure
2.3).
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Figure 2.3. Hsp31 is a methylglyoxalase that produces D-lactic acid.
(A) The plot of substrate concentration versus rate of D-lactate production by Hsp31 is
depicted and the michaelis-menten best fit model is represented by the solid line and was
the Vmax and Km were determined based on this model. Mean values of triplicate
experiments are plotted. Error bar = 1 SD. (B) GC-MS trace demonstrates a peak (6.09
min) consistent with the production of D-lactic acid by Hsp31 in the enzymatic reaction.
(C) The hyperbolic plot of substrate concentration versus rate of D-lactate production by
Hsp31 (circles), MORF Hsp31 (squares) and DJ-1 (triangles) are shown and the solid line
represents the Michaelis-Menten best-fit model. The Vmax parameters were determined
based on this model.
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We next determined if methylglyoxalase activity is required for rescue of α-syn toxicity.
One copy of α-syn-YFP decreases fitness in the hsp31Δ strain but GPD driven expression
of Hsp31 rescues that toxicity. The expression of GPD driven Hsp31 C138D restored the
α-syn expressing strain to full viability comparable to expression of the wild-type Hsp31.
The lack of enzyme activity for this mutant and ability to rescue α-syn toxicity indicated
that the in vivo mechanism of rescue is not dependent on methylglyoxalase activity
(Figure 2.4).
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Figure 2.4. The enzyme activity of Hsp31 is not necessary for rescuing α-syn toxicity.
Overexpression of pGPD HSP31 or the C138D mutant rescues toxicity from α-syn
expressing strains.
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MGO is a toxic metabolite produced during glycolysis that reacts with proteins to yield
toxic AGE and has been associated with increased α-syn cross-linking and formation of
intracellular foci formation in neuroblastoma cells (261,264,290,306-308). We examined
if increased levels of MGO could increase the α-syn foci or toxicity by treating cells with
exogenous MGO and found no increased foci formation in wild-type yeast indicating that
foci formation is likely not influenced by MGO. In addition, the hsp31Δ strain also did
not have increased foci suggesting that lack of Hsp31 is not sufficient to increase foci
formation due to MGO treatment. We determined that MGO was toxic to wild-type yeast
at 10 and 20 mM MGO and viability in the hsp31Δ strains was similar to WT suggesting
that Hsp31 is not sufficient for detoxification. The concomitant expression of α-syn (one
or two copies) and treatment with MGO did not have differential effects on viability
(Figure 2.5). Consistent with these results is that cell lysates of the hsp31Δ strain had
equivalent levels of overall methylglyoxalase activity as wild-type because other yeast
methylgloxalase enzymes, Glo1 and Glo2, are present in yeast and have been shown to
detoxify MGO.
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Figure 2.5 MGO does not increase α-syn foci or toxicity.
(A) Representative fluorescence microscopy images of α-syn expressing cells treated
with 2 mM and 20 mM MGO. (B) The level of α-syn foci does not increase with MGO
treatment. Percentage of cells with α-syn foci formation was quantified for the two strains
(α-syn-YFP and α-syn-YFP/hsp31Δ) in the presence of 2 mM and 20 mM MGO. Cells in
three or more fields of view were counted and the mean values plotted (Error bar = 1 SD)
ns= one-way ANOVA with multiple comparison t test indicates no significant difference.
(C) MGO treatment does not differentially increase toxicity of α-syn expressing strains
compared to non-expressing counterparts. Strains were serially diluted on agar plates
containing 10 mM and 20 mM MGO.
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2.3.3

D-lactate supplementation suppresses the steady state level of α-syn

Since, Hsp31 is a methylglyoxalase that converts MGO into D-lactate we further
investigated the possibility that deletion of HSP31 causes the toxicity in α-syn expressing
strains due to compromise in the glutathione-independent methylglyoxalase activity of
Hsp31. We explored if the lack of enzyme activity leads to a build up toxic cellular MGO
or if the altered phenotype of the strain results from the lack in enzymatic product i.e. Dlactate. More recently, it was shown that supplementing the cell with D-lactate restores
the mitochondrial membrane potential in DJ-1 deficient (RNAi-treated) HeLa cells (291).
We tested if external lactate supplementation could cure the α-syn toxicity similar to
Hsp31. First, we performed dilution growth assays on media containing lactic acid to
observe any rescue effect in α-syn expressing cells. Surprisingly, there was improved
growth of cells even in the presence of low levels of 0.2% lactic acid compared to cells
grown without lactic acid supplementation. In parallel to the dilution growth assay, we
performed microscopy on cells grown in liquid media containing lactic acid along with
galactose to induce α-syn expression and observed these cells under microscope. Cells
that were grown in media containing lactic acid showed reduced expression of α-syn
compared to non-treated cells. We further confirmed the reduced expression level of αsyn protein in cells treated with lactic acid through western blot analysis using α-syn
specific antibody. These results showed that although supplementation with lactic acid
reduces α-syn toxicity the mechanism is due to a decreased expression of α-syn, which
has been demonstrated to be concentration dependent (1 copy of pGAL-α-syn is not as
toxic as 2 copies of pGAL-α-syn). It is not clear how lactate supplementation affected the
steady state level of α-syn. Further studies would be needed to determine if transcription
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of α-syn was reduced or if post-translational regulation events affected the overall level
of α-syn (Figure 2.6).
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Figure 2.6 Effect of D-lactate on α-syn toxicity.
(A) Effect of D-Lactate on α-syn toxicity as analyzed by dilution growth assay. Fivefold
serial dilution of indicated yeast strain was spotted onto plates. Cells were grown for 3
days at 30 °C. (B) α-syn expression was induced for 24hrs in the presence and absence of
D-Lactate. Cell lysate were subjected to 10%SDS-PAGE and probe with α-syn specific
antibody. (C) Fluorescence microscopy of yeast cells expressing α-syn -YFP. Cells were
supplemented with 0.2% D-lactate for 12hrs with α-syn expression turned on. Cells that
were treated with D-lactate showed a suppressed α-syn expression (upper panel).
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2.3.4

Hsp31 prevents formation of large prion aggregates

The demonstration that Hsp31 possesses chaperone activity in a variety of antiaggregation assays prompted us to investigate if Hsp31 could also modulate the
oligomeric state of yeast prion proteins, such as the Sup35 prion. The aggregation state of
prions in living cells can be monitored by fusion of fluorescent protein tags to Sup35 PrD,
so we overexpressed Hsp31 to determine if it modulated the aggregation of Sup35 PrD.
Consistent with previous findings, cells overexpressing PrD in the presence of
endogenous Sup35 showed characteristic ribbon- like or punctate aggregates, which are
localized around the vacuoles or/and adjacent to plasma membranes. The cells coexpressing pAG415-GPD-HSP31-DsRed and pAG424-GAL-PrD- Sup35-EYFP had
approximately 3 fold less Sup35 fluorescent aggregates compared with cells harboring
pAG424-GAL-PrD-Sup35-EYFP plus vector control, indicating that Hsp31 can inhibit
the formation of microscopically visible Sup35 prion aggregates (figure 2.7A-B). The
intrinsic fluorescence of Sup35-EYFP appears to increase upon aggregation, which
allowed us to utilize flow cytometry as an alternative method to quantitatively measure
and show decreased Sup35 aggregation. This phenomenon has not been exploited widely
but was noted in at least one previous study investigating the aggregation of a
Huntington-GFP fusion protein (309). Cell cultures co-expressing Sup35 and Hsp31 used
in the microscopy experiments were prepared for flow cytometry and analyzed for EYFP
fluorescence intensity. The flow cytometry results were similar to the microscopy results
because Hsp31 expressing cells consistently exhibited lower median Sup35-EYFP
fluorescence intensity when compared with cells containing Sup35-EYFP expression
plasmid and empty vector. Individual traces depicting the number of counting events for
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each yeast strain also showed the decrease in cellular fluorescence intensity when Hsp31
is expressed (Figure 2.7).
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Figure 2.7. Fluorescence microscopy demonstrating Hsp31 suppression of Sup35
aggregation
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(A) PrD-Sup35 produced ribbon-like and punctate aggregates that are decreased when
Hsp31 is overexpressed. PrD-Sup35-EYFP was overexpressed for 48 h at 30° C in
control W303 cells or W303 cells expressing elevated levels of Hsp31. Hsp31 was
diffuse in the cytoplasm and decreased the presence of Sup35 aggregates. The diffuse
cytoplasmic localization of Hsp31 did not appear to be altered as a result of Sup35
expression. (B) Quantitation of cells with one or more Sup35-EYFP foci. A smaller
proportion of cells with Sup35 aggregates were evident in Hsp31 overexpressing cells
compared to vector control (pGPD). Values represent mean ±SEM (n = 3). (*** twotailed Student's t-test; p≤0.001). (C) Tracing of fluorescence obtained by flow cytometry
(D) Quantitation of Sup35-EYFP fluorescence suppression by Hsp31 using flow
cytometry. Hsp31 overexpression lowers the median fluorescence intensity (FI – arbitrary
units) of Sup35 compared to empty vector control. (* two-tailed Student's t-test; p≤0.05)
(±SEM error bars; n = 3 biological replicates).
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Expression of Hsp31 with the GPD promoter was diffuse and cytoplasmic, and varied in
intensity in individual cells across the total cell population. The cytoplasmic localization
profile of Hsp31 was not altered when PrD-Sup35 was expressed. Interestingly, we
observed overlapping localization in cells with Sup35 aggregates and relatively high
levels of Hsp31 but the proteins do not appear to mutually co-localize. In some cells it
was evident that the DsRed signal was decreased in the area where there was a Sup35
aggregate suggesting that Hsp31 is not incorporated in aggregates. The aggregate appears
to occlude Hsp31 and the diffuse overlapping signal observed in some cells is consistent
with the presence of Hsp31 throughout the cytoplasm surrounding the aggregate (Figure
2.8).
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Figure 2.8 Hsp31 and Sup35 are not mutually co-localized.
Most cells with high levels of expression of Hsp31 and Sup35 exhibited diffuse
cytoplasmic localization for Hsp31 that overlapped with Sup35 (Top panel). Occlusion of
Hsp31 from the Sup35 aggregate was also observed as evidenced by the decreased
DsRed signal at aggregate sites (white arrows – bottom panel).
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We also confirmed that Hsp31 overexpression reduces the formation of in vivo
aggregates based on assessing cell lysates by SDD-AGE. We found that SDS-resistant
Sup35 aggregates were greatly reduced when Hsp31 was over-expressed. The positive
control, Hsp104, completely eliminated detectable Sup35 aggregates. These results are
consistent with the ability of Hsp31 to inhibit the formation of large protein aggregates.
We also ascertained if other chaperones are induced upon overexpression of Hsp31. We
demonstrated Hsp70 and Hsp104 expression are not altered and hence elevated
expression of these chaperones is not responsible for the observed suppression of prion
aggregates (Figure 2.9). This is in agreement with our in vitro aggregation studies
establishing that purified and recombinant Hsp31 protein is solely sufficient to prevent
protein aggregation although we cannot exclude the possibility that Hsp31 could
collaborate with other chaperones to prevent prion aggregation in the cell.

81
A
GAL-PrD-Sup35-EYFP +
GPD-Hsp104
GPD-Hsp31
Vector

+
+

+

+

-

+

-

+

+

SDD-AGE
IB: GFP

SDS resistant
Sup35 aggregates

SDS-PAGE
IB: GFP

Sup35 monomer

B
pGPD
pGPD Hsp31-DsRed

-

+!

-

+!

-

+!

-

+!

+

-!

+

-!

+

-!

+

-!

α-Hsp104

α-Hsp70

α-DsRed

α-actin

Figure 2.9. Hsp31 suppresses SDS resistant Sup35 aggregates
(A) Cellular lysates were subjected to SDD-AGE and SDS-PAGE. Overexpression of
Sup35-PrD-EYFP initiated the formation of Sup35 aggregates which were detected with
anti-GFP antibody (B) Hsp31 overexpression does not alter the expression levels of
Hsp104 and Hsp70. Immunoblots were probed with anti-Hsp104, anti-Hsp70, anti-DsRed
and anti-actin antibodies.
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2.3.5

Hsp31 rescue of α-syn -mediated toxicity is independent of the autophagy
pathway

In several recent studies, autophagy has been identified as one of the main mechanisms to
clear and recycle misfolded proteins and aggregates in the cytosol (310,311). In addition
to the ubiquitin proteasome system, autophagy is a major cellular function involved in
clearance of misfolded and aggregated proteins including α-syn aggregates (310).
Deletion of autophagy genes such as ATG5 or ATG7 leads to neurodegenerative disease
in mice (312,313). In yeast, deletion of ATG1 gene that is required for induction of
autophagy reduced the clearance of α-syn aggregates (314). Deletion of HSP31 was also
demonstrated to impair autophagy under carbon starvation conditions (152). These
studies raise the question that Hsp31 could be promoting autophagy of aggregated protein.
In order to exclude the possibility that the Hsp31 rescue effect on α-syn toxicity depends
on autophagy, we deleted the ATG8 gene in the α-syn strains and assessed the synthetic
lethal effects of α-syn expression in these strains. As expected, expression of α-syn in the
atg8Δ strain resulted in decreased viability compared to the wild-type strain. The atg8Δ
hsp31Δ strain had similar viability to the atg8Δ strain when α-syn is expressed. These
results confirm that autophagy is a protective mechanism against α-syn toxicity. The lack
of synthetic lethal defect between ATG8 and HSP31 with and without α-syn expression is
consistent with genes that are in the same pathway and hence do not buffer each other
(Figure 2.9).
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Figure 2.10 The autophagy pathway prevents α-syn toxicity but is not required for Hsp31
mediated rescue.
Yeast strains serially diluted on YEP agar plates (Glucose or Raffinose/Galactose)
demonstrating the toxicity of GAL-α-syn in the atg8Δ, hsp31Δ and atg8Δ hsp31Δ strains.
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Expression of Hsp31 and the C138D mutant in the autophagy strains, atg8Δ α-syn or
atg8Δ hsp31Δ α-syn, increased viability in rich YEP media compared to vector controls.
We found that the rescue effect in synthetic media was not easily observed because
expression of α-syn was not toxic in the atg8Δ strain background but it was toxic in
hsp31Δ indicating media conditions are an important factor in this complex relationship.
These results demonstrate that Hsp31 can rescue α-syn toxicity in autophagy deficient
cells (Figure 2.10).
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Figure 2.11 Effect of Hsp31 overexpression on atg8Δ strains
Overexpression of Hsp31 using pAG415-GPD-HSP31-DsRed or the C138D mutant
partially rescued toxicity of α-syn expression on YEP media for the atg8Δ, hsp31Δ and
atg8Δ hsp31Δ strains (right panel). Rescue by Hsp31 overexpression could not be
assessed in synthetic media for strains with the atg8Δ genotype because GAL-α-syn
expression not toxic in these strains (middle panel). Rescue of GAL-α-syn expression in
the hsp31Δ strain was toxic and rescued by Hsp31 overexpression in synthetic and YEP
media.
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2.4
2.4.1

Methods

Yeast cell growth conditions

Yeast media were prepared according to Amberg D C. et al. (315). Liquid yeast
extract/peptone dextrose (YPD) medium contained Bacto yeast extract (1%, Fisher
Scientific), Bacto peptone (2% Fisher Scientific) and glucose (2% Fisher Scientific).
Synthetic dextrose (SD) minimum liquid medium was made of 0.17% Difco yeast
nitrogen base (without amino acids), 2% glucose, and supplemented with necessary
amino acids for auxotrophic strains needed at concentrations described previously (315).
Solid medium plates were made with the same components of liquid medium plus 2%
agar (Fisher Scientific). To express galactose-inducible proteins, 2% raffinose
(Affymetrix, Cleveland OH) and 2% galactose (Affymetrix, Cleveland OH) were used to
replace glucose. Fractions of culture were obtained at designated times to monitor the cell
fitness and protein levels by OD600 and immunoblotting, respectively.
2.4.2

Spotting assay / Dilution growth assays

All the yeast strains were grown at 30 °C in 2% glucose minimal media overnight.
Strains were diluted to OD600 of 0.2 and grown in minimal media switching the carbon
source with 2% raffinose for overnight. Cultures were normalized to OD600 of 0.8 and 5X
serial dilutions were spotted onto the respected dropout plate containing 2% glucose or
Yeast strains construction galactose. Plates were grown at 30 °C for 2-3 days before
taking pictures.
2.4.3

Yeast strains construction

Yeast strains used in this study are listed in Table 2.1. The hsp31Δ and atg8Δ deletions
were generated in W303-1A or in a strain expressing one or two copies α-syn fused to
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fluorescent proteins (CFP and YFP) using the primers listed in Table 2.2. The
nourseothricin N- acetyl-transferase (NAT) gene flanked by Hsp31 homology regions
was obtained by PCR with 70 nucleotide long forward primer and reverse primer. The
primers consisted of 20 nucleotides for amplifying the NAT gene from pFA6a-natNT2
(Euroscarf), and 50 nucleotides immediately preceding the Hsp31 or Atg8 start codon or
after the stop codon. The amplified product was integrated into W303 α-syn expressing
strains at ChrIV:1502160 to 1501447 as described previously. For double knockout
hsp31Δ atg8Δ strain KanMX4 resistance cassette was used to delete Hsp31 and than
NATMX4 resistance cassette for deletion of ATG8.
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Table 2.1 List of strains used in this study
Strain

Genotype

Source or reference

BY4741

MATa his3, leu2, met15, ura3, ARL1,

Invitrogen

GCS1, ARL3, ARF3, YPT6, IMH1,
SYS1, GAS1
W303-1A

MATa can1-100 his3-11, 15 leu2-3,

R. Rothstein

112 trp1-1 ura3-1 ade2-1
W303-hsp31Δ

W303-1A hsp31Δ::NATMx

This study

W303-HSP31-

W303-1A HSP31-9myc::KanMX

This study

W303 GAL-α-syn-YFP at URA3 or

J-C. Rochet(316,317)

9myc
W303-1x α-syn

TRP1 loci
W303-2x α-syn

W303 GAL- α-syn-YFP at URA3 GAL-

J-C. Rochet

α-syn-CFP at TRP1 loci
W303-1x α-syn

W303 GAL- α-syn-YFP at URA3 or

HSP31-9myc

TRP1 loci HSP31-9myc::KanMX

W303-2x α-syn
HSP31-9myc

W303 GAL- α-syn-YFP at URA3 GAL-

This study
This Study

α-syn-CFP at TRP1 loci HSP319myc::KanMX

W303-hsp31Δ

W303-1A atg8Δ:: NATMx

This study

W303-hsp31Δ

W303-1A atg8Δ:: NATMx hsp31Δ::

This study

KanMx
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Table.2.2 List of plasmids used in this study
Plasmids

Type of

Source or reference

plasmid
pGEX6P-1 Hsp31

E. coli

This study

pAG415-GPD-Hsp31-dsRed

Yeast, CEN

This study

pAG415-GPD-ccdB-dsRed

Yeast, CEN

Alberti et al.(318)

pAG-425-GAL-PrD-Sup35-

Yeast, 2 µ

Alberti et al.(318)

p2HG

Yeast

Rochet’s lab

p2HG-Hsp104

Yeast

Rochet’s lab

BG1805 HSP31-MORF

Yeast, 2 µ

Gelperin,D.M.,et al.(319)

EYFP
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Table 2.3. List of primers used in this study.
Primer name

Primer sequence (5’! 3’)

HSP31_NAT_F

AAGTACTTCCCACTGGCTAATTACACAGATAAAACTCA
AACAAATTTATAATGACATGGAGGCCCAGAATACCC

HSP31_NAT_R

CTTACATCTATATAGTAGTACAAAGGAAATTCTAATTA
TCAACCTTTGGCTCACAGTATAGCGACCAGCATTCAC

Hsp31_9myc_F

TCTGCGCACTCCACTGCCGTAAGATCCATCGACGCTTT
AAAAAACCGTACGCTGCAGGTCGAC

Hsp31_9myc_R

TCCTTACATCTATATAGTAGTACAAAGGAAATTCTAAT
TATCAACCTTTGGCTCAATCGATGAATTCGAGCTCG

HSP31-9myc tag

ACAGAGAATTAACGTTACTC A TTCC

diagnostic-F
HSP31-9myc tag

ATATTTGGATATTGGGGAAACAC AT

diagnostic-R
Atg8-NAT_F

AGTTGAGAAAATCATAATAAAATAATTACTAGAGACA
TGACATGGAGGCCCAGAATACCC

Atg8-NAT_R

CGATTTTAGATGTTAACGCTTCATTTCTTTTCATATAAA
AGACTACAGTATAGCGACCAGCATTCAC

ATG8 diagnostic-F GGGAACCATTAAAGGTTGAG GAGG
ATG8 diagnostic-R GTAAACATTCTTATACTGGAACA
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2.4.4

HSP31 9myc tagging

We endogenously tagged HSP31 with 9myc epitope using a PCR- based integration. The
pYM20 plasmid was used as template and appropriate primer set to obtain PCR product
with HSP31 genomic flanking sequence and the PCR product was transformed into
W303 and W303 α-syn-CFP + α-syn-YFP strains. The transformants were selected on
media containing hygromycin B (300mg/L) and correct integration was verified by PCR
using primers spanning the integration junctions and by DNA sequence analysis. DNA
manipulation - The plasmids used in this study are listed in Table 2.2. Hsp31 was shuttled
into pAG415- GPD-ccdB-DsRed (Addgene Cambridge MA (318) from pDONR221 with
LR clonase (Invitrogen, Grand Island, NY) to produce pAG415-GPD- HSP31-DsRed.
Both DJ-1 and Hsp31 were cloned into BamHI/XhoI sites of pGEX 6p-1. pESC-Leu
myc-HSP31 was constructed by cloning at the XhoI/NheI sites. The HSP31 gene was
amplified from yeast genomic DNA. The Hsp31 C138D mutant was prepared by PCR
amplification using pAG415-GPD-Hsp31-DsRed as template and set of primers listed in
Table 2.3 Each successfully mutated insert was sequenced to confirm the mutation.
2.4.5 Antibodies and immunoblotting
To determine protein expression yeast cells were collected by centrifuging at 5000 rpm
and pellets were resuspended in extraction buffer (50mM Tris-HCl pH 7.5, 1mM EDTA,
4mM MgCl2; 5mM DTT). Glass beads (Sigma, St. Louis, MO) were added into the
mixture, which was vortex 5 times for 10 s each, plus 1 min intervals on ice. Clear crude
protein lysate was obtained by spinning down the cell debris at 1000 xg at 4 °C for 10
min. The SDS- PAGE loading dye (4 % SDS, 40 % glycerol, 0.02% bromophenol blue,
Tris-Cl, pH6.8) was added to supernatant and samples were boiled, followed by SDS-
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PAGE and immunoblotting with antibodies. Monoclonal anti-myc and anti-β-actin
antibody were purchased from Sigma-Aldrich (St. Louis, MO). Monoclonal anti-α-syn
was obtained from BD biosciences (San Jose, CA). The following antibodies were also
used to detect expression of Hsp104 (Abcam; ab69549), Hsp70 (Stressgen; SPA-82);
DsRed (Santa Cruz Biotechnology; Sc-33353) and GFP (Roche; anti- GFP).
2.4.6

Protein purification

BY4741 harboring yeast Hsp31 expression plasmid from the yeast moveable ORF
collection (Thermo Fisher Scientific Open Biosystems, Huntsville, AL) was used to
express and purify the protein. We did not see any evidence of co-purifying proteins on
SDS-PAGE gels and observed similar high activity from protein purified under high salt
conditions, which minimizes contaminant co-purifying proteins. Human DJ-1 was
encoded in pGEX 6p-1 (GE Healthcare Life Sciences), hchA was encoded in pNT-hchA,
and α-syn was expressed from the pT7 plasmid. The protein expression and purification
was described previously. Briefly, constructs were transformed into BL21 (DE3) cells.
The transformants were grown to an OD600 of 0.4 – 0.6 in LB medium supplemented with
100 µg/ml ampicillin at 37 °C, and Isopropyl β-D-1- thiogalactopyranoside (IPTG) (1mM
as final concentration) was added to induce protein expression. After 3 h of induction at
37 °C, cells were harvested by centrifugation at 2,000xg, and re-suspended in lysis buffer
(25 mM KPi pH 7.0, 200mM KCl) containing protease inhibitor cocktail set IV
(Calbiochem, Billerica, MA). Crude protein was prepared by sonicating cells and
clarifying the lysate by centrifugation at 10,000xg for 10 min. GST tagged DJ-1 was
immobilized by Glutathione agarose resin (Thermo scientific) and DJ-1 was eluted by
cleaving from the GST tag with PreScission Protease (GE Healthcare Life Sciences,
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Pittsburgh, PA) (2 units of protease for every 100 µg of tagged DJ-1) leaving a linker
amino acid sequence: (NPAFLYKVVDVSRHHHGRIFYPYDVPDYAG LEVLFQ)
The protein was approximately 95% pure based on band intensity coomassie blue
staining with SDS- PAGE.
2.4.7

Dilution growth assays

Plasmids pAG415-GPD- ccdB-DsRed and pAG415-GPD-HSP31-DsRed were
transformed into W303 α-syn expressing strains with or without genomic copy of the
HSP31 gene knocked out using the PEG/lithium acetate transformation method. Single
colonies of transformants were grown in SD-Leu overnight, the cells were washed,
normalized and grown in synthetic complete without leucine (SC-Leu) + raffinose (2%)
to switch the carbon source. After incubating in the raffinose medium over night, the cell
number was normalized, and spotted on SD-Leu (suppressed expression) plate and SCLeu with 2% raffinose and 2% galactose (induced expression) with five-fold serial
dilutions. The plates were incubated at 30 °C for 3 days.
2.4.8

Fluorescence imaging analysis α-syn localization

pESC-Leu myc-Hsp31 and control empty vector were transformed into 2 copies of α-syn
expressing strain. Transformants were inoculated and grown as described in the growth
dilution assay. The α-syn expression was induced by growing the cells in synthetic
minimum medium with 2% raffinose and galactose for 8 h. The live cells were visualized
using Nikon TE2000-U inverted fluorescence microscope with Nikon Plan apochromat
60X (NA 1.4) oil immersion objective and YFP filters plus 300X magnification. In order
to differentiate the localization of protein, approximately 50 individual cells were
randomly counted in multiple regions of interest for each set of experiment. The ratio of
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membrane to cytoplasmic localization of α-syn fluorescent fusion protein was presented
as the mean from three independent sets of experiments.
2.4.9

MGO addition and microscopy

α-syn expressing strains with or without the Hsp31 gene deleted were grown in YPD
media and transferred into media containing 2% galactose and MGO (0.5mM-2mM) for
6 h and 12 h. Cells were washed and subjected to confocal microscopy to observe α-syn
foci formation. The presence of MGO inhibited the growth of cells for the initial 12 h and
resulted in equal growth rate between strains regardless of the Hsp31 gene deletion.
Strains could not be grown in the presence of high concentrations of MGO (20mM) so αsyn was induced for 10 h and then MGO was added and incubated for another 2 h before
confocal microscopy analysis.
2.4.10 Assessment of intracellular ROS
Cells were harvested after induction of α-syn expression for 12 h and 5 × 106 of cells
were prepared to stain with dihydroethidium (DHE). Cells were suspended in 250 µl of
2.5 µg/ml DHE in PBS, and incubated in the dark for 10 min. Cells were washed in the
PBS and were subjected to fluorescence microscopy (excitation at 485 nm and emission
at 520 nm) and flow cytometry with FL-2 channel. FlowJo software was used to calculate
median fluorescence intensity.
2.4.11

Prion expression experiments

W303 WT strain was co-transformed with pAG424-GAL- PrD-Sup35-EYFP and
pAG415-GPD-HSP31-DsRed. Single transformations were also performed using the
same constructs and their corresponding control vector. Cells were grown at 30°C in
appropriate medium overnight (SD-Trp for pAG424, SD-Leu for pAG415 and SD-Trp-
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Leu for co-transformants) and protein expression was induced for 24 h in SC 2%
Raffinose and 2% Galactose containing medium at 30 °C. After induction, cells were
subjected to fluorescence microscopy using a Nikon A1 confocal microscope with a
Nikon Plan apochromat 60X (NA 1.4) oil immersion objective to acquire fluorescence
and DIC images and were analyzed using Image J. The identical cultures used in
microscopy were used to prepare samples for flow cytometry, cells were washed and resuspended in PBS at a density of ~10x106 cells/ml. Cells were filtered and analyzed for
EYFP fluorescence intensity using a flow cytometer with the FL-1 channel. A total of
10,000 events were acquired for each sample and data was analyzed using FlowJo
software to calculate median fluorescence intensity after three biological replicates.
2.4.12 Glutathione-independent glyoxalase biochemical Assay
Purified recombinant Hsp31 and Hsp31 C138D with GST tag removed were used to
assay methylglyoxalase activities. The reaction was initiated by adding specified
concentration of proteins (1 µM Hsp31 and 5 µM Hsp31C138D) in reaction buffer (100
mM HEPES, pH 7.5, 50 mM KCl, 2 mM DTT) to 6 mM initial concentration of MGO
(Sigma, 40% solution), followed by incubation at 30 °C. The assay was performed, by
removing 50µl aliquots of the reaction at fixed time points (15, 30, 45, and 120 s) after
addition of protein. The amount of D-lactic acid produced by Hsp31 as a result of MGO
consumption was measured. The initial rate obtained was divided by amount of protein in
the reaction mixture to calculate the specific activity. Samples were also subjected to Gas
Chromatography-Mass Spectroscopy analysis (Agilent 5975C MSD) to identify the
presence of D-lactic acid. Samples were derivatized with N, O-bis (trimethylsilyl)
trifluoroacetamide) and trimethylchlorosilane and heated to 50 °C for 10 min and run in
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the electron impact mode with scanning from 42-400 atomic mass units. A lactic acid
standard displayed a peak at 6.09 min identical to the peak detected in the Hsp31-treated
sample whereas Hsp31C138D did not display this peak. The spectral scan was visualized
and displayed using the OpenChrom software (320). To obtain the enzymatic parameters,
the reaction was initiated as described above by adding 1 µM Hsp31 or 5 µM
Hsp31C138D protein into reaction buffer and reactions were stopped after 1 min by
heating at 85 °C for 30 s. A range of MGO substrate from 50 µM to 2 mM and the
EnzyFluo D-Lactate Assay kit (Bioassay System) was used to determine the amount of
D-lactic acid produced in each reaction. Each rate was determined in triplicate and mean
values were plotted to obtain enzymatic parameters (Vmax and Km) by fitting to
michaelis-menten model using Graphpad prism.
2.4.13 Semi-denaturing detergent-agarose gel electrophoresis (SDD-AGE)
W303 cells harboring pAG424-GAL-cPrDSup35-EYFP and pAG415-GPD-HSP31DsRed plasmids were used and aggregates produced by inducing for 24 h in SC 2%
raffinose + 2% galactose media. Prion aggregates were analyzed using SDD-AGE (321).
Briefly, to prepare lysates, cells were harvested by centrifugation at 3,000'g for 2'min and
re- suspended in spheroplast solution (1.2 M D-sorbitol, 0.5 mM MgCl2, 20 mM Tris (pH
7.5), 50 mM β-mercaptoethanol and 0.5 mg/ml Zymolyase and incubated at 30 °C for 30
min with shaking. After spheroplast formation the samples were centrifuged at 800 rpm
for 5 min at room temperature and supernatant was removed. The pelleted spheroplasts
were resuspended into 100 µL lysis buffer (100 mM Tris 7.5, 50 mM NaCl, 10 mM βmercaptoethanol and protease inhibitor and vortexed at high speed for 2 min. The lysates
were collected and mixed with 4 x sample buffer (2 x TAE; 20 % glycerol; 4 % SDS;
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0.01% bromophenol blue). The samples were incubated at room temperature for 15 min
and loaded onto a 1.8 % agarose gel containing 1 x TAE and 0.1 % SDS and run at 50 V,
followed by transfer onto nitrocellulose membrane using capillary transfer method. The
nitrocellulose membrane was subjected to western blot analysis using anti-GFP antibody
(Roche). A strain harboring p2HG-Hsp104 plasmid was included as a positive control.
2.5

Discussion

DJ-1/ThiJ/PfpI superfamily members composed of structurally similar proteins that are
present in prokaryotes and eukaryotes. Often these proteins are associated with stress
response. However, structural and biochemical studies have proven that they are diverse
in functions with the ability to perform multiple activities that include chaperone,
protease, methylglyoxalase, deglycase and role in autophagy. In this study we aimed to
delineate the functions of Hsp31 by using yeast as a model. Recently, we established that
Hsp31 is a potent chaperone that can inhibit the aggregate formation of large number of
proteins such as insulin, citrate synthase as well as prevent α-syn fibrillization in vitro
and α-syn toxicity in vivo. Because Hsp31 is a multifunctional protein, we sought to
identify the interaction between different functional pathways of Hsp31 and define its
role in protecting against cellular stress. We also obtained insight into the role of Hsp31
in Sup35 prion aggregations.
2.5.1

Role of Hsp31 in redox homeostasis

Previous studies showed the protective effect of Hsp31 under oxidative and proteotoxic
stress in that overexpression of Hsp31 protect yeast cell viability under these conditions
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(260,303). In the past, our lab has shown that Hsp31 protects cells from α-syn mediated
toxicity. These observations led us to explore the expression profile of Hsp31 in response
to oxidative and proteotoxic stress. A genomically tagged strain shows an increase in
Hsp31 expression under both oxidative and proteotoxic stress (Figure 2.1). Previous
studies have shown that an increased level of Hsp31 at the diauxic shift and during
stationary phase of growth cycle. These phases in the growth cycle are associated with
stress due to accumulation of toxic metabolites and lack of nutrients (322). An elevated
level of Hsp31 at later phases of growth indicates that it could possibly be due to the
stress associated with these phases. HSP31 expression is also induced when yeast cells
are treated with H2O2 to produce oxidative stress and this up-regulation of HSP31 in
response to ROS has been reported to be under the control of stress responsive
transcription factor Yap1, as removal of Yap1 binding site (-363 and -353 bp relative to
the ATG) from HSP31 promoter has shown to reduce Hsp31 expression under oxidative
stress (303). However, we observed that this shortened promoter also eliminates another
stress response element (STRE, a CCCCT site at -379 to -383 from the ATG) in addition
to the Yap1 binding site. STREs are the binding site for Msn2/4, and several other stressrelated yeast genes have been documented to be transcriptionally activated by these
transcription factors, including genes up-regulated after the diauxic shift in stationary
phase cells (303).
Finally, we also reported an increase in ROS levels upon HSP31 deletion that correlates
with increased toxicity by α-syn expression compared to WT strains, as level of
superoxide was higher when we overexpressed α-syn indicating that the presence of
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Hsp31 is important in reducing ROS to basal levels. A previous study has shown that αsyn expression is associated with caspase-mediated ROS generation (323) (Figure 2.2). In
agreement with our study, overexpression of HSP31 robustly suppresses both cytosolic
and mitochondrial ROS levels instigated by MGO and H2O2 and therefore provide
cytoprotection. In addition, Hsp31 localizes to mitochondria and preserves mitochondrial
integrity by redistributing glutathione to the cytoplasm under oxidative stress (260).
Another study examined the deglycase activity of Hsp31 and showed that it may
efficiently deglycate proteins with glycated Cys, Arg and Lys amino acid residues (265).
Taken together, these results suggest that Hsp31 is an integral part of the heat shock
protein system and plays a vital role in maintaining cellular homeostasis. These results
establish that Hsp31 has a role in response to ROS and its expression is induced in
response to several types of stress.
2.5.2

Hsp31 chaperone activity is independent of its methylglyoxalase activity

Recently in our lab we demonstrated the robust chaperone activity of Hsp31 that can
rescue the α-syn toxicity in vivo. A question was raised that the in vivo rescue effects
could have been mediated by the Hsp31 methylglyoxalase activity or interaction with
other biological pathways such as the metabolic or autophagy pathway. First we
confirmed that Hsp31 does have methylglyoxalase activity and demonstrated that
mutation of the catalytic triad residue, C138D, results in greatly reduced
methylglyoxalase activity (Figure 2.3). However, this mutation did not inactivate the
chaperone activity in terms of rescuing the cells from α-syn-mediated toxicity when
expressed under GPD-HSP31 C138D system (Figure 2.4). Furthermore, we showed that
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that exogenous MGO did not differentially affect viability suggesting that Hsp31 does not
rescue by reducing accumulation of this toxic metabolite in α-syn expressing cells
(Figure 2.5). Another study also reported that mutation in the catalytic triad largely
abolishes glyoxalase activity but this catalytic triad is not required for chaperone activity
of Hsp31 (260). These results indicate that the anti-aggregation activity of Hsp31 is not
under the influence of its known enzymatic activity rather; it has a direct chaperone
activity against misfolded proteins. Intriguingly, all the paralogs of the Hsp31 minifamily
possess comparable activity against α-syn aggregation and toxicity when they are
overexpressed from the GAL promoter (106). However, unlike Hsp31, the other paralogs
possess very little methylglyoxalase activity and are unable to protect the cells from
glyoxal toxicity (260). Furthermore, the chaperone activity of Hsp31, Hsp32 and Hsp33
against a cytoplasmic aggregation-prone protein is independent of their role in oxidative
stress response and the vacuolar degradation pathway (262). These results again support
the notion that anti-aggregation activity of Hsp31 mini-family is independent of its
enzymatic activity.
2.5.3

Autophagy pathway is not essential for chaperone activity of Hsp31

We also demonstrated the autophagy pathway is an important mediator in the α-syn
toxicity because deletion of ATG8 resulted in synthetic lethal interaction with α-syn
expression (Figure 2.10). This is consistent with atg1Δ or atg7Δ strains having synthetic
lethal interactions with α-syn expression and having defects in clearing α-syn foci (324).
However, we show that hsp31Δ atg8Δ strain does not have increased α-syn- mediated
toxicity when compared to atg8Δ, consistent with these genes occurring within the same
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synthetic lethal pathway. A recent result indicates that hsp31Δ strains are defective in
autophagy (301) so the additional deletion of an autophagy gene should not increase
toxicity. Interestingly, overexpression of Hsp31 in these autophagy deficient strains can
rescue cells from α-syn toxicity indicating that autophagy pathway is not essential for
chaperone rescue (Figure 2.11). Autophagy may be beneficial for controlling α-syn
toxicity but it appears that chaperone activity of Hsp31 is also important.
2.5.4

Hsp31 inhibits Sup35 prion aggregation

Several orthologous experiments suggest that Hsp31 intervenes early in the misfolding
process and prevents the formation of larger oligomeric species. Previously, we showed
that the addition of Hsp31 to α-syn monomers in a fibrillization assay resulted in a
baseline level of ThioT fluorescence signal indicating that the formation of larger
oligomeric species was prevented. Analysis of the SDS-resistant oligomeric species by
SDS-PAGE demonstrated that the presence of Hsp31 prevented the formation of higher
order oligomeric α-syn species. Here, our studies demonstrate the ability of Hsp31 to
prevent prion aggregation in vivo and in vitro. Our results indicate that Hsp31 inhibits
prion assembly before the formation of visible subcellular YFP-tagged PrD aggregates
and those detected by SDD-AGE (Figure 2.7, Figure 2.9). Furthermore, the Sup35
aggregates occlude Hsp31, indicating that the anti-aggregation activity of Hsp31
commences prior to the formation of the visible aggregate and probably does not act to
remove or disassemble any preformed aggregates (Figure 2.8). This is in contrast to large
chaperones, Hsp104, Ssa1/2, Sis1 and Sse1, which mutually co-localize with prion
aggregates (325). A previous study has demonstrated that small HSPs can inhibit
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formation of Sup35 aggregates and found that Hsp26 and Hsp42 inhibit rare transient
oligomers at distinctly different steps in the prion formation process (53). Further studies
are done to determine Hsp31 role in inhibiting prion aggregation. These results are listed
in Chapter 3. Overall, we demonstrate that Hsp31 can inhibit oligomerization or
aggregation of α-syn and Sup35 by intervening early in the process.
2.5.5

Yeast purified MORF-Hsp31 is more potent than recombinant Hsp31 or DJ-1

Intriguingly, Hsp31 purified directly from a yeast expression system, the GAL promoter
induced movable ORF tag system (MORF) (319), had increased enzymatic activity
compared to Hsp31 purified from recombinant E. coli (Figure 2.3). We also
demonstrated that the yeast-purified protein was more active in preventing aggregation of
several substrate proteins including α-syn. The increased activity may be due to the
difference in the affinity tags used or fusion tag orientation, that has been previously
observed for E coli Hsp31 (256,271) but, it may be a result of posttranslational
modification(s) that occur in the cell. Several reports have indicated that posttranslational modifications or differing levels of oxidation of the cysteine residue can
alter activity of DJ-1 (297,326). We also show that Hsp31 is a more potent
methylglyoxalase compared to DJ-1 consistent with several other studies (Figure 2.3)
(260,261). In addition, we have shown that yeast Hsp31 is more active in preventing
protein aggregation compared to DJ-1. Interestingly, it has also been observed that
Hsp31 rescues α-syn and Huntingtin’s toxicity to a greater extent than DJ-1 in vivo
(106,299). These results raise the intriguing possibility that Hsp31 is constitutively active
whereas DJ-1 must undergo an activation event to increase its activity.
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2.6

Conclusion and future directions

Recent studies have demonstrated the facility of yeast to investigate pathogenic
mechanisms underlying α-syn toxicity including the identification of novel biological
pathways that impinge on α-syn biology and small molecule modulators of α-syn toxicity
(314,327). In addition, the action of Hsp31 on α-syn may provide insight into the mode of
toxicity of α-syn because recent evidence suggests that the α-syn toxic species is smaller
than the visible aggregate (314).
Our results together with other recent findings demonstrate the multitasking ability of
Hsp31, which is particularly important during stressful situations. It functions as a stress
response chaperone, glutathione independent methylglyoxalase, has a role in the
autophagy pathway and acts as a deglycase. Other possible functions have been observed
for this superfamily including a report of RNA binding for DJ-1 and protease activity for
other family members (328-330). These multiple functions can modulate the protein
misfolding and stress pathways at various points in the cellular network but our results
also highlight that Hsp31 has the ability to inhibit protein aggregation distinct of its
enzymatic activity (Figure 2.12). We believe that Hsp31 acts at the initial phases of
protein misfolding process and prevents the formation of larger aggregates but does not
possess disaggregase activity.
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Figure 2.12 The homeostatic functions of Hsp31 associated with protecting cells from
stress.
Hsp31 is a methylglyoxalase that converts MGO into D-lactate independent of
glutathione. Proteotoxic stress induced the expression of Hsp31, which exerts a protective
function against toxic effect of oligomers in yeast cells. Oxidative stress induces the
expression of Hsp31, re-localizes it to mitochondria resulting in reduced levels of ROS.
Response to other stresses leads to Hsp31 localization to P bodies and stress granules.
HSP31 deletion under carbon starvation compromises the autophagy pathway, which is a
pathway used to clear oligomerized or aggregated proteins. Despite the role of Hsp31 in
autophagy, it has a protective effect against α-syn oligomerization independent of its role
in autophagy because of its inhibitory effect early in the oligomerization process.

105
We have established a framework that extends the yeast model for investigating
mechanisms of α-syn toxicity in the context of the DJ-1/ThiJ/PfpI superfamily in yeast.
Extension of this work will assist elucidating the chaperone-like mechanisms of Hsp31,
and a comparison with DJ-1 may provide evolutionary insights into the activities of the
DJ-1/PfpI/ThiJ superfamily family. Our model may also be used to further delineate the
nature of oligomeric species in the pathogenesis of PD and possibly what species of αsyn should be targeted therapeutically.
Given the apparent functional diversity of Hsp31 revealed so far, it is likely that there
might be other chaperone dependent and independent functions of this protein that may
exist. Many HSPs work in collaboration with other chaperone in order to be fully active.
The exploration and identification of protein-protein interaction partners of Hsp31 would
provide insight on mechanism and roles of Hsp31. There is s dearth of protein-protein
interaction information for Hsp31 although it was reported to interact with other
chaperones according to a large-scale proteomic study (28). Deletion of HSP31 downregulates the Ssa3, a Hsp70 paralog, mRNA level at stationary phase suggesting a
correlation between Hsp31 and Hsp70 activity (114). Human homolog DJ-1 is known to
interact with many chaperones including Hsp70 and mitochondrial Hsp70 indicating that
translocation of DJ-1 to mitochondria depends on these chaperones (304). A distinct
possibility is that relocation of Hsp31 to mitochondria, P bodies or stress granules under
oxidative stress is dependent on interactions with other chaperones. Our data support that
Hsp31 acts at early stages of protein aggregation do not delineate the stage of
intervention and therefore further investigation is needed. Hsp31 may interact with
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unfolded monomers to sequester them from progressing to oligomers or alternatively, it
might become active only after smaller oligomers are formed.
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CHAPTER 3. THE SMALL HEAT SHOCK PROTEIN HSP31 COOPERATES WITH
HSP104 TO MODULATE THE SUP35 PRION

3.1

Abstract

The yeast homolog of DJ-1, Hsp31, is a multifunctional protein that is involved in several
cellular pathways including detoxification of the toxic metabolite MGO and as a protein
deglycase. Prior studies ascribed Hsp31 as a molecular chaperone that can inhibit α-syn
aggregation in vitro and alleviate its toxicity in vivo. It was also shown that Hsp31
inhibits Sup35 aggregate formation in yeast. However, it is unknown if Hsp31 can
modulate [PSI+] phenotype and Sup35 prionogenesis. Other small heat shock proteins
(sHSPs), Hsp26 and Hsp42 are known to be a part of a synergistic proteostasis network
that inhibits Sup35 prion formation and promotes its disaggregation. Here, we establish
that Hsp31 inhibits Sup35 [PSI+] prion formation in collaboration with a well-known
disaggregase, Hsp104. Hsp31 transiently prevents prion induction but does not suppress
induction upon prolonged expression of Sup35 indicating that Hsp31 can be overcome by
larger aggregates. In addition, elevated levels of Hsp31 do not cure [PSI+] strains
indicating that Hsp31 cannot intervene in a pre-existing prion oligomerization cycle.
However, Hsp31 can modulate prion status in cooperation with Hsp104 because it
inhibits Sup35 aggregate formation and potentiates [PSI+] prion curing upon
overexpression of Hsp104. The absence of Hsp31 reduces [PSI+] prion curing by Hsp104
without influencing its ability to rescue cellular thermotolerance. Hsp31 did not synergize
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with Hsp42 to modulate the [PSI+] phenotype suggesting that both proteins act on similar
stages of the prion cycle. We also showed that Hsp31 physically interacts with Hsp104
and together they prevent Sup35 prion toxicity to greater extent than if they were
expressed individually. These results elucidate a mechanism for Hsp31 on prion
modulation that suggest it acts at a distinct step early in the Sup35 aggregation process
that is different from Hsp104. This is the first demonstration of the modulation of [PSI+]
status by the chaperone action of Hsp31. The delineation of Hsp31’s role in the
chaperone cycle has implications for understanding the role of the DJ-1 superfamily in
controlling misfolded proteins in neurodegenerative disease.
3.2

Introduction

Amyloids are highly ordered cross β-sheet protein polymers that are associated with a
broad range of neurodegenerative diseases including PD, AD, HD and Prion diseases
(16,331). Growth of amyloids occurs by the nucleated polymerization of soluble proteins
of a particular sequence (69,332). Many proteins can polymerize to form amyloid when
provided an appropriate environment in vitro, indicating this as inherent characteristic of
polypeptides. Indeed, many recent studies have shown the existence of beneficial
amyloids that are important for survival of a host organism (185). Furthermore, the
highly rigid structure of self-propagating amyloids provides a possible tool in designing a
unique nanomaterial (333). Therefore, it is important to study the process of amyloid
formation as well as its modulation.
The budding yeast Saccharomyces cerevisiae provides a useful model to understand the
formation, modulation and disaggregation of amyloids including prions (182). One of the
most extensively studied yeast prions is the translation termination factor Sup35, which
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has the normal function of releasing polypeptide chains from the ribosome upon
encountering a stop codon. The prion form of Sup35 involves a self-perpetuating
conformational change that results in stop codon suppression and translational readthrough (180). This termination defect can be visualized easily in vivo by nonsense
suppression of a designed premature stop codon in a gene that affects colony color, thus
providing a convenient phenotypic assay to monitor [PSI+] prion (180).
The propagation of [PSI+] prion in yeast is rigorously controlled by molecular chaperone
machinery including, Hsp104, Hsp70, Hsp40 and their co-chaperones (40,232,334).
Hsp104 is a member of AAA+ ATPase superfamily and its expression is induced under
stress to facilitate refolding and dissociation of protein aggregates (228,335). A moderate
level of Hsp104 is required for [PSI+] prion propagation as overproduction or deletion of
Hsp104 cures the [PSI+] prion in yeast (45,222). Since Hsp104 disaggregates the
misfolded protein after heat shock, it is postulated that Hsp104 generates “propagons” by
fragmenting the prion polymers that are available for further polymerization and
therefore maintain the prion propagation (182). Another model proposes that elevated
levels of Hsp104 cure [PSI+] prion by dissolution of the prion seeds. The evidence for
this model came from the observation of the diffuse expression of Sup35 tagged with
GFP when Hsp104 was overexpressed in [PSI+] cells, (229) and a large fraction of
soluble Sup35 was observed in the cell lysate of [PSI+] with excess of Hsp104 expression
(187). Recent studies also suggests that dissolution of prion seed might be due to
trimming activity of Hsp104 in which Sup35 dissociates from the end of the prion seed
thus reduces its size without generating new seeds (223,233). Trimming activity of
Hsp104 is still present even when severing activity is inhibited by treatment with
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guanidine (233). Hsp104 collaborates with Hsp70 and Hsp40 families in dissolution of
heat-damaged proteins as well as prion propagation (38,39,225,227,336,337).
Interestingly, different Hsp70 homologues have opposing effects on [PSI+] in which the
Ssa proteins antagonize while the Ssb proteins potentiate [PSI+] curing by elevated levels
of Hsp104 (40,224,238). Deletion of co-chaperones of Hsp70/90, such as Sti1 or Cpr7,
also inhibit [PSI+] curing by Hsp104 overexpression (40).
In addition to Hsp104 and its assistant chaperones, sHSPs such as Hsp31, Hsp26 and
Hsp42 also play a role in disaggregation of misfolded proteins in yeast
(53,240,242,243,262,299,338). These proteins are highly expressed under moderate stress
and during late growth phase for transition to stationary phase (262,294). Hsp42 and
Hsp26 work synergistically to inhibit prion formation and potentiate dissolution of Sup35
prion aggregates by distinct mechanisms (53). Furthermore, Hsp26 or Hsp42 collaborate
with Hsp70 and or Hsp104 to reduce the SDS-resistant polyglutamine aggregation
(234,243). Hsp31 inhibits the formation of α-syn aggregates in vitro and toxicity in vivo
(106,158). It was also demonstrated that Hsp31 inhibits Sup35 aggregation formation in
yeast (158) However, it is unknown whether Hsp31 interferes with [PSI+] prion induction
and propagation and if like other sHSPs it can coordinate with Hsp104.
In the present study, we aimed to explore the role of Hsp31 in prion propagation and
induction using [PSI+] prion model. We investigated the ability of Hsp31 to inhibit
Sup35 prion aggregation and induction by overexpression of the prion-forming domain
(PrD) in [psi-] strain. In this study we have delineated the collaboration between Hsp31
and Hsp104 on [PSI+] prion curing and prion associated toxicity. These results are the
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first evidence that Hsp31 acts as a chaperone protein that coordinates with Hsp104 to
rescue cells from prion toxicity.
3.3
3.3.1

Results

Hsp31 antagonizes the Sup35 aggregation formation in [psi- PIN+] strain
background.

We previously reported that Hsp31 has chaperone activity against Sup35 aggregates
when tested in the wild-type (WT) W303 yeast strain. In this study, we validated the
ability of Hsp31 to inhibit Sup35 fibril formation in the [psi- PIN+] strain background.
[PIN+], an epigenetic element, is required to induce [PSI+] formation spontaneously or by
overexpression of Sup35 or its PrD (181). The presence of [PIN+] is necessary at early
stages of prion formation but is not needed for maintenance and propagation of [PSI+]
(182). We overexpressed Hsp31-DsRed under the GPD promoter concomitantly with
PrD-Sup35-EYFP under GAL expression in a [psi- PIN+] strain. When examined by
confocal microscopy, PrD-Sup35 fluorescent foci were greatly reduced in cells coexpressing pAG415-GPD-HSP31-DsRed and pAG424-GAL-PrD- Sup35-EYFP as
compared to empty vector control (Figure 3.1 A-B). We further confirmed reduced foci
formation by measuring fluorescence intensity using flow cytometry and obtained similar
results as fluorescence microscopy (Figure 3.1C). We have previously observed and
established that Sup35 aggregates are associated with increased fluorescence and can be
quantified using flow cytometry (158). Finally, we performed semi-denaturing detergent
agarose electrophoresis (SDD-AGE) to determine the level of SDS-resistant aggregate
forms. Consistent with the previous results, elevated Hsp31 greatly reduced the level of
Sup35 aggregates as measured by SDD-AGE but did not greatly reduce the overall
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steady-state level of Sup35 in SDS-PAGE (Figure 3.1D). These results show that Hsp31
can prevent de novo [PSI+] aggregate formation in the presence of the [PIN+] genetic
element.
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Figure 3.1. Hsp31 overexpression decreases the level of PrD-Sup35 aggregates.
(A) GAL-driven PrD-Sup35-EYFP was overexpressed for 24 h at 30 °C in [psi- PIN+]
cells with or without overexpression of DsRed tagged Hsp31. PrD-Sup35-EYFP
aggregates appeared as ribbon-like vacuolar peripheral rings. Hsp31 remains
cytoplasmically diffuse in these cells. Elevated levels of Hsp31 decreased the presence of
Sup35 aggregates in individual cells. (B) Quantitation of the number of cells with one or
more Sup35-EYFP foci. The average of at least three independent experiments was
plotted; error bars represent mean ±SEM. (*** unpaired Student's t-test; p≤0.001). (C)
Quantitation of the level of Sup35-EYFP fluorescence aggregates using flow cytometry.
Aggregates are associated with higher fluorescence. Elevated levels of Hsp31 lowered
the median fluorescence intensity (FI – arbitrary units) of Sup35-EYFP compared to
empty vector control. Values represent mean ±SEM of three independent biological
replicates (* unpaired Student's t-test; p≤0.01). (D) Cellular lysate of cells describe in A
and B was analyzed by semi-denaturing agarose electrophoresis and SDS-PAGE.
Overexpression of Hsp31 suppresses the level of SDS-resistant Sup35 aggregates as
detected with anti-GFP antibody. Lower panel shows the expression of Hsp31 detected
by anti-DsRed antibody.
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3.3.2

Hsp31 transiently inhibits Sup35 prion induction in vivo

The ability of Hsp31 to inhibit Sup35 aggregation in the [psi- PIN+] background led us to
investigate its ability to inhibit [PSI+] induction. Spontaneous de novo [PSI+] induction
frequency is extremely low unless Sup35 or its PrD is overexpressed (180,189). This
system is widely used to investigate the process of prion induction in yeast. To determine
whether Hsp31 can inhibit prion induction we used a [psi- PIN+] strain that forms red
color colonies on ¼ YPD plates with limited adenine. This strain forms white colonies in
the presence of [PSI+] because soluble Sup35 is depleted by aggregate formation
resulting in suppression of a premature stop codon and restoration of adenine prototrophy.
We observed that overexpression of Hsp31 antagonized [PSI+] prion induction triggered
by overexpression of Sup35 PrD for 6 h (Figure 3.2A-B). However, when Sup35 PrD
was expressed for 12 or 24 h, the [PSI+] prion induction rate between empty vector and
Hsp31 was statistically similar (Figure 3.2C). These findings suggested that Hsp31
antagonizes prion induction transiently but can be overcome by excess production of PrD
or cannot intervene when cells have established a full and more mature prion cycle.
These results are consistent with our previous proposal that Hsp31 intervenes early in the
protein misfolding processes (158,339).
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Figure 3.2. Hsp31 transiently inhibits Sup35 prion induction.
(A) To induce prion formation, a GAL-driven vector expressing PrD-Sup35-EYFP was
expressed in the [psi- PIN+] strain containing the ade1-14 nonsense mutation.
Constitutive expression of Hsp31 was driven by the GPD promoter and [PSI+] formation
was scored by quantifying white color colonies on ¼ YPD plates. Plates were grown for
2-3 days at 30 °C and incubated at 4 °C for increased color development. Plasmids
expressing Hsp42 and Hsp104 were added as positive controls. (B) PrD-Sup35-EYFP
was expressed for 6 h to transiently induce prion formation. Hsp31 overexpression
decreased the prion induction rate. Error bars represent ±SEM (** unpaired Student's ttest; p≤0.001, n=3). (C) Time course of prion formation by pAG424-GAL-PrD-Sup35EYFP with varied expression times in the presence of GPD-Hsp31. Error bars represent
mean ±SEM (** unpaired Student's t-test; p≤0.001, n=3) ns= not significant. All
experiments in this figure were biological replicates.
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3.3.3

[PSI+] prion state is not affected by Hsp31 overexpression or deletion

Transient overexpression of sHSPs such as Hsp26 and Hsp42 cure the [PSI+] prion,
converting white colonies of [PSI+] into red colonies of [psi-] on ¼ YPD plates with
limited adenine (53). First, we tested if overexpression of Hsp31 can cure the [PSI+]
prion. Despite the fact that Hsp31 can prevent de novo prion aggregate formation in vivo
as detected by SDD-AGE (Figure 3.1), overexpression of Hsp31 is not sufficient to cure
the [PSI+] prion phenotype (Figure 3.3A). In addition, Hsp42 was used as a control and
was able to cure [PSI+] as previously reported (53). However, we found that Hsp26
overexpression using the identical plasmid vector from Duennwald et al. (53) could not
cure [PSI+] in this strain and under these experimental conditions. Our results are more
consistent with Wickner and colleagues (340) who reported lack of prion curing by
Hsp26 for both [Ure3-1] and [PSI+] phenotypes, which could be explained by differences
in strain genotypes and experimental conditions (340). We tested different plasmid
systems to express Hsp31 including the GPD and GAL promoters and none of them were
able to modulate the [PSI+] prion phenotype (data not shown). Next, we determined if
deletion of HSP31 influences the [PSI+] prion status. We constructed a [PSI+ PIN+]
hsp31Δ strain carrying the reporter nonsense allele ade1-14, so that the Sup35 readthrough caused by [PSI+] presence could be detected by development of white colonies.
The phenotype of the [PSI+] prion was similar in the hsp31Δ strain compared to WT with
no change in colony color (Figure 3.3B), suggesting that Hsp31 cannot intervene in an
established prion cycle.
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3.3.4

Hsp31 deletion impairs [PSI+] prion curing by Hsp104 overexpression

A moderate level of Hsp104 is required for maintenance of [PSI+]; either deletion or
overexpression of Hsp104 cures the [PSI+] prion. Numerous chaperones such as Hsp70,
Hsp40 and Hsp90 along with its co-chaperones Sti1 and Cpr7 are known to modulate
prion curing by Hsp104 (39,40). To determine if Hsp31 altered Hsp104-mediated [PSI+]
prion curing, we transformed WT [PSI+] or hsp31Δ [PSI+] cells with p426-GPD-Hsp104
(low level of overexpression), pAG425-GAL-Hsp104-DsRed (medium overexpression) or
p2HG-Hsp104 (high overexpression GPD) plasmids (Figure 3.3C-E). The varied
overexpression level of Hsp104 under these different plasmid systems was confirmed by
western blotting (Figure 3.3F). The rate of [PSI+] prion curing was correlated to the level
of Hsp104 expression in WT [PSI+] cells. The rate of [PSI+] prion curing was
significantly reduced in hsp31Δ [PSI+] under the lowest overexpression condition of
GPD-Hsp104 (2% compared to 7% in WT) (Figure 3.3C). Under high overexpression of
Hsp104, a 100% curing rate was observed in the presence of HSP31 but the hsp31Δ strain
never achieved 100% curing rates and clearly white colonies were observed at 3%
frequency (Figure 3.3D). Induction of the GAL-Hsp104-DsRed construct for varied time
points from 2 h to 72 h also showed consistently less efficient prion curing by the hsp31Δ
strain (Figure 3.3E). The decreased prion curing in the hsp31Δ [PSI+] strain background
was not due to decreased Hsp104 expression because we observed a similar expression
level compared to WT (Figure 3.5B). These results demonstrate the presence of Hsp31 is
required for optimal prion curing efficiency at varied Hsp104 expression conditions.
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Figure 3.3. Hsp31 is required for optimal Hsp104-induced curing of the [PSI+]
phenotype
(A) To determine the effect of Hsp31 on [PSI+] prion curing, the WT and hsp31Δ [PSI+]
strains harboring the GPD-Hsp31 expression vector (pAG415-GPD-Hsp31-DsRed) or
the empty vector (pAG415-GPD-ccdB-DsRed) were grown for 12 h at 30 °C before
plating on ¼ YPD plates. (B) The WT and hsp31Δ [PSI+] strains with no vector were also
grown and treated in the same way. Plates were grown for 2-3 days at 30 °C and
transferred at 4 °C for increased color development. No difference in colony color was
observed in these strains. (C) Low-level overexpression of Hsp104 was used to induce
prion curing in [PSI+] hsp31Δ and WT strains. Cells were grown in liquid media for 12 h
at 30 °C before plating on ¼ YPD plates. Significantly less prion curing was observed in
the [PSI+] hsp31Δ strain (**unpaired Student's t-test; p≤0.001, n=3). (D) High-level
overexpression of Hsp104 was used to induce prion curing in [PSI+] hsp31Δ and WT
strains. A 100% curing rate was observed in WT strain. In the [PSI+] hsp31Δ strain, 100%
curing was never achieved. White color colonies were plotted for the WT and [PSI+]
hsp31Δ strain (****unpaired Student's t-test; p≤0.0001, n=3 biological replicates). (E)
Hsp104 expression under the GAL promoter for 2 to 72 h in WT and [PSI+] hsp31Δ strain.
At each indicated time point, cells were plated on ¼ YPD plates. Percentage of prion
curing was calculated at each point for both WT and [PSI+] hsp31Δ strain. The plotted
graph is one representation of three independent biological repeats. (unpaired Student's ttest; p≤0.001 at 24, 48 and 72 h; n=3). (F) Western blot demonstrating the relative
expression levels of Hsp104.
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3.3.5

Hsp31 collaborates with Hsp104 to cure [PSI+] prion

The decreased efficiency in Hsp104 curing [PSI+] in the absence of Hsp31 lead us to
further explore the relationship between these two chaperones. Small HSPs Hsp26 and
Hsp42 are known to collaborate with Hsp104 in rescuing the polyglutamine toxicity and
solubilization of amyloid aggregates (243). We aimed to test the effect of expressing
Hsp31 and Hsp104 together in curing of the [PSI+] prion. Expression of Hsp104 (p426GPD-Hsp104) in the [PSI+] strain resulted in a curing rate of 3 % that is lower than the
rate in Figure 3.3 because the co-existence of two different constructs decreases plasmid
copy numbers and affects expression levels. Co-expression of Hsp31 and Hsp104
increased the rate of prion curing to 6 % compared to the respective controls (Figure
3.4A-B). We also tested the collaboration between Hsp104 and Hsp31 in the hsp31Δ
strain and detected that co-expression of Hsp104 with Hsp31 was able to cure the [PSI+]
prion to a greater extent than individual chaperone expression (Figure 3.4C-D). These
results corroborate the inefficient curing in hsp31Δ and establish that Hsp31 is required
for optimal Hsp104 activity.
Previously, it was shown that sHSP, Hsp42, collaborates with Hsp26 to prevent [PSI+]
prionogenesis by distinct and synergistic mechanisms with Hsp104 (53), hence we tested
the interaction between Hsp42 and Hsp31 on [PSI+] prion curing. Elevated levels of
Hsp42 driven by the GPD promoter was sufficient to increase curing of [PSI+] in this
strain transformed with a single plasmid (5.4% compared to 1.4%). Introduction of a
second empty vector plasmid decreased the curing rate of the GPD-HSP42 construct to
background levels. We also co-expressed Hsp31 and Hsp42 in the [PSI+] strain and did
not detect any increased curing rate, in contrast to Hsp31 co-expression with Hsp104
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(Figure 3.4E-F). This lack of synergy between these proteins implies that Hsp42 and
Hsp31 act at a similar stage of the prion cycle.
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Figure 3.4. Expression of Hsp31 in combination with Hsp104 increases the rate of prion
curing.
(A) Hsp31 and p426-GPD-Hsp104 were co-transformed in the [PSI+] strain. Empty
vectors served as controls. (B) Quantification of the experiments in panel A. Prion curing
rate was increased from about 2.5% to 6% when Hsp31 was co-expressed with Hsp104
compared to the control strain (*unpaired Student's t-test; p≤0.001, n=3). (C) [PSI+]
hsp31Δ strain harboring plasmids for Hsp104 and Hsp31. (D) Quantification of
experiments describe in panel C. The combination of Hsp104 and Hsp31 increased the
rate of prion curing in [PSI+] hsp31Δ strain consistent with WT strain in A-B. (** Oneway ANOVA; p≤0.001, n=3). (E) Image of p426-GPD-Hsp42 transformed cells
demonstrating curing compared to empty vector. (F) Hsp31 and p426-GPD-Hsp42 were
co-transformed in the [PSI+] strain and quantified. The combination of Hsp42 and Hsp31
did not increase the curing rate (ns=not significant). Data and images shown are
representative of at least three independent biological experiments for all panels.
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3.3.6

Effect of [PSI+] curing in the hsp31Δ strain is not due to loss of Hsp104
thermotolerance function.

A possible mechanism for the decrease in [PSI+] prion curing by Hsp104 in the hsp31Δ
background is decreased expression or activity of Hsp104. To measure the functional
competence of Hsp104 we tested the thermotolerance activity of Hsp104 in exponentially
growing cells. We induced Hsp104 expression in both strains by incubating the culture at
37 °C for 30 minute and then heat shocked at 50 °C. The survival of cells after heat shock
is dependent on Hsp104 induction, and we observed the rate of survival in hsp31Δ was
comparable to the isogenic WT [PSI+] strain (Figure 3.5A). Moreover, the basal
thermotolerance without induction of Hsp104 was not affected by deletion of Hsp31
(Figure 3.5A). In addition, we observed a slightly elevated level of Hsp104 in the hsp31Δ
strain compared to WT, hence the expression of Hsp104 is not compromised (Figure
3.5B). Thus, reduction in [PSI+] prion curing in the hsp31Δ strain is not due to general
impairment of Hsp104 activity or expression.
3.3.7

Hsp104 physically interacts with Hsp31

The close collaboration between Hsp104 and Hsp31 prompted us to test the physical
association between them. Co-immunoprecipitation followed by western blot analysis in
yeast lysates demonstrated that Hsp31 interacts with Hsp104. Immunoprecipitation was
performed using HSP31-9myc genomically tagged at the endogenous locus and
overexpressing Hsp104 either under the GPD or the GAL promoter. First, Hsp31-9myc
was pulled down using anti-myc antibody conjugated to agarose beads from
exponentially growing cell lysates. Western blots confirmed the successful pull down of
Hsp31-9myc (Figure 3.5C; middle panel). The upper panel demonstrates the successful
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pull-down of Hsp104 in both GPD-HSP104 and GAL-HSP104 expressing lysates but not
in the empty vector control (Figure 3.5C). Similar results were obtained with an
alternative co-immunoprecipitation approach in which polyclonal anti-Hsp104 antibody
and protein G dynabeads were used to pull down Hsp104 followed by western blot
analysis with anti-myc antibody to detect Hsp31. This approach confirmed the
interactions and also demonstrated that Hsp31 is pulled down with strains having
endogenous levels of Hsp104 (Figure 3.5C; bottom panel empty vector lane). These
results demonstrate that Hsp31 is part of same complex with Hsp104 using two different
immunoprecipitation protocols and the Hsp31-Hsp104 interaction is detectable under
physiological expression levels.
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Figure 3.5. Hsp31 interacts with Hsp104 and deletion of HSP31 does not alter Hsp104’s
thermotolerance response.
(A) HSP31 deletion does not impair Hsp104’s function in thermotolerance. Exponentially
growing cells of the [PSI+] hsp31Δ and [PSI+] strain was drawn from the culture and
decimal serial dilutions were plated onto YPD plates and incubated for 2 days at 30 °C in
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each case. Both strains showed a comparable basal tolerance (top right image) and
induced tolerance after pretreatment at 37 °C (bottom right image) for 30 min to a 50 °C
heat shock treatment. Left images are non-treated cultures that serve as control. (B)
Endogenous level of Hsp104 was determined in exponentially growing cultures of [PSI+]
hsp31Δ and [PSI+] strains in YPD media using Hsp104 specific antibody. (C)
Immunoprecipitation of Hsp31 from HSP31-9myc strain with overexpression of Hsp104
either under GPD or GAL promoter, using anti-myc antibody followed by
immunoblotting with anti-Hsp104 antibody. Empty vector served as a control. Middle
panel shows the successful pull down of Hsp31-9myc in all strains using anti-myc
antibody. The lower panel Hsp104 was immunoprecipitated using anti-Hsp104 antibody
followed by immunoblotting with anti-myc antibody.
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3.3.8 Hsp31 together with Hsp104 antagonizes prion dependent toxicity of excess
Sup35.
Overexpression of full length Sup35 or its PrD exhibits toxicity in the [PSI+] strain
(244,246). The toxicity of excess Sup35 in [PSI+] or [PSI+] hsp31Δ strain was
investigated. Deletion of HSP31 has no effect on Sup35 toxicity (Figure 3.6) in contrast
to our previous report of increased toxicity when α-syn is expressed in the hsp31Δ strain
background (158). However, elevated levels of Hsp31 expressed from the GPD promoter
rescued [PSI+] cells from Sup35 toxicity in both WT and deleted strains. As expected,
Hsp104 reduce the toxicity of Sup35 to greater extent than Hsp31. Strikingly, Hsp31
together with Hsp104 strongly reduced the toxicity of Sup35 in the [PSI+] strain (Figure
3.6). We also observed the rescue effect of sole expression of Hsp31 or Hsp104 and when
expressed together in the [PSI+] hsp31Δ strain. The level of rescue was not as dramatic as
in the WT strains suggesting that the expression of endogenous Hsp31 has a role in
reducing toxicity in conjunction with heterologous expression of Hsp31 or Hsp104. The
role of endogenous Hsp31 is not clear but could be a direct effect of chaperone activity or
because autophagy can be impaired in hsp31Δ strains (294) which may lead to increased
proteotoxicity of Sup35.
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Figure 3.6. Hsp31 and Hsp104 reduce Sup35 prion toxicity.
Hsp31, Hsp104 or the indicated combination of both along with GAL-PrD-Sup35-EYFP
or full length Sup35 were overexpressed in [PSI+] and [PSI+] hsp31Δ strains. Decimal
serial dilutions were plated onto selection plates with 2% glucose that serve as control or
2% galactose to induce the expression. Plates were incubated at 30 °C for 3 days before
producing the images. Hsp31 or Hsp104 rescued toxicity of GAL-PrD-Sup35-EYFP or
full length Sup35 in these strains. Combination of Hsp31 and Hsp104 greatly reduce the
toxicity compared to when they are individually expressed.
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3.3.9

Hsp31 and Hsp104 modulate Sup35 aggregation in [PSI+] cells

Collaboration of Hsp31 with Hsp104 to reduce Sup35 induced prion toxicity prompted us
to investigate whether this activity correlates with protein disaggregation activity of
Hsp104. To assess the state of Sup35 in [PSI+] cells harboring Hsp31 and Hsp104, we
performed sedimentation analysis to determine the ratio of Sup35 in the soluble versus
aggregate forms. The individual expression of Hsp104 or Hsp31 resulted in a very strong
signal in the insoluble pellet fraction. However, the combination of Hsp104 and Hsp31
markedly reduced Sup35 aggregation found in the pellet fraction and increased the
amount of Sup35 found in the soluble fraction (Figure 3.7A). Soluble Sup35 was very
susceptible to proteolysis during processing of the samples as evident by the lower
molecular weight species, which is consistent with earlier reports (187,341). These results
demonstrate that sole overexpression of Hsp31 does not appear to intervene in the
established prion cycle present in a [PSI+] strain but can inhibit aggregate formation and
prionogenesis in a [psi-] strain (Figure 3.1). However, the results also show that Hsp31
can cooperate with Hsp104 to reduce Sup35 toxicity and simultaneously increase Sup35
solubility.
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Figure 3.7. Hsp31 acts early in the prionogenesis process.
Hsp31 together with Hsp104 decrease the aggregation of Sup35 formed by
overexpression of GAL-PrD-Sup35-EYFP. Crude lysates of cells expressing Hsp31,
Hsp104 or both together were subjected to sedimentation analysis. Lysates were
ultracentrifuged into P (pellet) and S (soluble) fractions and analyzed by immunoblotting
using GFP-specific antibody.
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3.4
3.4.1

Material and Methods
Yeast strains and plasmids

The [psi-, PIN+] and [PSI+] strains were used throughout the study for prion induction,
curing and toxicity assays. The W303 HSP31-9myc strain was used for pull down assays.
Details of the plasmid, strains and primers used in this study are provided in the tables
(Table 3.1-3.3). Deletion of HSP31 in [PSI+] strain was obtained by transforming a PCR
product containing the nourseothricin N- acetyl-transferase (NAT) gene flanked by
HSP31 homology regions. The primers consisted of 20 nucleotides for amplifying the
NAT gene from pFA6a-NATNT2 (Euroscarf), and 50 nucleotides immediately preceding
the HSP31 start codon or after the stop codon. The amplified product was integrated into
[PSI+] and [psi-, PIN+] strain. Successful integration and deletion was confirmed by
diagnostic PCR.
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Table 3.1 List of yeast strains used in the study.
Strain

Genotype

Source/reference

[PSI+] 74D-

MATa ade 1-14, his3, leu2, trp1, ura3

J-C. Rochet

694

[PSI+ PIN+]

W303-1A

MATa can1-100 his3-11, 15 leu2-3, 112

R. Rothstein

trp1-1 ura3-1 ade2-1
[PSI+]-

W303-1A hsp31Δ::NATMX

This study

W303-1A HSP31-9myc::KANMX

This study

hsp31Δ
W303HSP31-9myc
[psi-] 74D-694 74D-694 MATa ade 1-14, his3, leu2, trp1, J-C. Rochet
ura3 [psi- PIN+]
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Table 3.2 List of plasmids used in the study
Plasmids

Type of

Source/reference

plasmid
pAG415GPD-HSP31-dsRed

Yeast, CEN This study

pAG415ccdB-dsRed

Yeast, CEN Alberti et al.(318)

pAG424GAL-PrD-Sup35EYFP
pLA1-Sup35
p426-GPD
p426-GPD-Hsp42
p426-GPD-Hsp104
p2HG-GPD-Hsp104
p2HG-GPD
pAG425-GAL-ccdB-DsRed
pAG425-GAL-Hsp104-DsRed

Yeast, 2 µ

Alberti et
al.(180,318)

Yeast

J. Shorter(53)

Yeast

J. Shorter(53)

Yeast

J. Shorter(53)

Yeast

J. Shorter(53)

Yeast

J-C.Rochet

Yeast

J-C.Rochet

Yeast, 2 µ

Addgene

Yeast, 2 µ

This study
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Table 3.3 List of primers used in the study
Gene/description

Forward

Reverse

hsp31Δ

AAGTACTTCCCACTGGC

CTTACATCTATATAGTAGTACA

TAATTACACAGATAAAA

AAGGAAATTCTAATTATCAAC

CTCAAACAAATTTATAA

CTTTGGCTCACAGTATAGCGAC

TGACATGGAGGCCCAGA CAGCATTCAC
ATACCC
9myc tagging of TCTGCGCACTCCACTGC

TCCTTACATCTATATAGTAGTA

HSP31

CGTAAGATCCATCGACG

CAAAGGAAATTCTAATTATCA

CTTTAAAAAACCGTACG

ACCTTTGGCTCAATCGATGAAT

CTGCAGGTCGAC

TCGAGCTCG

AAACTCGAGATGGCCCC

TTTGCTAGCTCAGTTTTTTAAA

AAAAAAAGTTTTACTCG

GCGTCGATGGATCTTAC

HSP31 cloning

C
HSP31 9myc tag ACAGAGAATTAACGTTA

ATATTTGGATATTGGGGAAAC

diagnostic

CTCATTCC

ACAT

hsp31Δ

TTCGTGGTCGTCTCGTA

GCAGGGCATGCTCATGTAGA

diagnostic

CTC
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3.4.2

Yeast growth conditions

We used isogenic [psi-] and [PSI+] derivatives of 74D-694 [MATa, his3, leu2, trp1, ura3;
suppressible marker ade1-14. Cells were grown at 30 °C on synthetic dextrose medium
(SD; 0.7% yeast nitrogen base, 2% glucose) with appropriate amino acid dropout mixture
for selection and maintenance of the particular plasmid. Synthetic complete (SC) medium
contains 2% raffinose in place of glucose and 2% galactose for induction of genes under
the GAL promoter. ¼ YPD solid medium used in the plating assays contains 0.5% yeast
extract, 2% peptone, and 2% glucose. Cultures were always maintained in actively
growing conditions and OD600 was used to measure the growth rate.
3.4.3

SDD-AGE

The [psi-] cells were co-transformed with pAG424-GAL-PrD-Sup35-EYFP and pAG415GPD-HSP31-DsRed plasmids. Cultures were grown in SD media overnight and induced
in SC 2% raffinose + 2% galactose media for 24 h. Prion aggregates were analyzed using
SDD-AGE as described previously(158). Briefly, cells were harvested by centrifugation
and spheroplasts were generated and lysed in 4 x SDS sample buffer at room temperature
for 15 min before loading onto a 1.8 % agarose gel followed by transfer to nitrocellulose
membrane. The membrane was immune-blotted using anti-GFP antibody (Roche;
11814460001) and anti-DsRed antibody (Santa Cruz Biotechnology; Sc-33353).
3.4.4

Fluorescence Microscopy and flow-cytometry

The [psi-] strain was co-transformed with pAG424-GAL-PrD-Sup35-EYFP and pAG415GPD-HSP31-DsRed. Successful transformation was selected and re-streaked on SD (tryptophan -leucine) agar plates. Cells were grown overnight at 30 °C in SD (-tryptophan
-leucine) medium and PrD-Sup35 expression was induced for 24 h in SC (-tryptophan -
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leucine) medium with 2% raffinose and 2% galactose. Cells were examined under
fluorescence microscopy using a Nikon A1 confocal microscope with a Nikon Plan
apochromat 60 X (NA 1.4) oil immersion objective to acquire fluorescence and DIC
images and were analyzed using Image J. The identical cultures used in microscopy were
also subjected to flow cytometry. After induction cells were collected and washed with
PBS, filtered and analyzed for EYFP fluorescence intensity using the Beckman Coulter
FC500 flow cytometer with the FL-1 channel. A total of 10,000 events were acquired for
each sample and data was analyzed using FlowJo software to calculate median
fluorescence intensity.
3.4.5

Sup35 prion curing

Curing of [PSI+] was performed by transforming the strain with plasmids, p2HG-GPDHsp104, pAG425-GAL-Hsp104, pAG415-GPD-HSP31-DsRed, p426-GPD-Hsp42 and
their corresponding empty vectors. For double transformation both plasmids were cotransformed and selected on double dropout media simultaneously. Transferred cells
were grown in the SD medium at 30 °C for overnight growth and plated on ¼ YPD plates
which were incubated for three days at 30 °C and shifted for another day at 4 °C for
colony color development. To score for curing, colonies with red color were counted as
[psi-]. Cultures carrying plasmid with the GAL promoter were grown in SC medium
before plating on ¼ YPD.
3.4.6

Sup35 prion induction

For the induction experiment, at least three independent transformants with pAG424GAL-PrD-Sup35-EYFP and pAG415-GPD-HSP31-DsRed plasmid were grown at 30 °C
in SD medium overnight, centrifuges and washed three times with water, and shifted to
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SC medium to induce prion formation. Aliquots were withdrawn at 6, 12 and 48 h and
diluted to a density of 50,000 cells per 100 µl for plating onto ¼ YPD plate. The plates
were then incubated for three days at 30 °C and another day at 4 °C for color
development. Percentage of [PSI+] induction was measured as the number of white ([PSI+]
colonies) colonies divided by the total number of colonies.
3.4.7

Prion toxicity assay

The [PSI+] strain was transformed with pAL1 Sup35 and plasmids expressing Hsp31,
Hsp42 and or Hsp104 along with their corresponding empty vector. After selection on SD
plates, cells were grown into 5 ml of SD liquid media with 2 % glucose at 30 °C
overnight. Cells were harvested and washed three times with water and a five fold serial
dilution was performed with a starting OD600 of 0.8. Diluted samples of 5 µl were spotted
onto SD and SC plates with the appropriate dropout selection. Plates were incubated at
30 °C for 3 days and imaged with a scanner.
3.4.8

Pull down assay

The HSP31-9myc tagged strain was transformed with plasmids pAG425-GAL-Hsp104 or
p426-GPD-Hsp104. Cells lysates were prepared in a buffer (50 mM Tris–HCl, 1 mM
EDTA, 5 mM DTT, 10% (v/v) glycerol, 0.5 M NaCl, at pH 7.5) with freshly added
protease inhibitor cocktail (Roche). Anti-myc antibody-conjugated agarose beads were
used to pull down Hsp31 protein by incubating the beads with the lysate at 4 °C for 1 h.
After the pull down, beads were washed three times with PBS-T and bound protein was
eluted by boiling the sample in SDS loading buffer before separating the proteins on
SDS-PAGE and western blotting using Hsp104 antibody (Abcam; ab69549).
Immunoprecipitation was also preformed in reverse by immobilizing Hsp104 antibody on
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protein G dynabeads (Life Technology) and incubating the total cell lysate with this
complex for 1 h. In this case, western blotting was performed using anti-myc antibody
(Sigma; M4439).
3.4.9 Thermotolerance assay
WT [PSI+] and [PSI+] hsp31Δ strains were grown in YPD medium starting from OD600 of
0.2 until they reach exponential growth phase after 6 h. Equal number of cells from each
strain were incubated at 37 °C to induce Hsp104 expression and then heat shocked at
50 °C for 20 min. Aliquots were placed on ice before and after heat shock. A portion of
cultures were heat shocked at 50 °C without Hsp104 induction at 37 °C. Samples were
collected and five-fold dilutions were spotted on YPD medium.
3.4.10 Sedimentation assay
[PSI+] strains harboring Hsp31, Hsp104 and appropriate co-expression vector plasmids
were grown for 12 h and centrifuged to collect cells. Cells were washed in water and
lysed at 4 °C by bead beating in lysis buffer (50 mM Tris HCl pH 7.5, 50 mM NaCl, 2
mM EDTA and 5% Glycerol plus freshly added protease inhibitor cocktail(158)). Equal
volume of cold RIPA buffer (50 mM Tris HCl pH 7.0, 150 mM NaCl, 1% Triton X-100,
0.5% deoxycholate and 0.1 % SDS) was added to the lysate and the mixture was vortexed
for 10 s. Lysate was centrifuged at 800 rpm for 2 min at 4 °C in a Eppendorf
microcentrifuge. Lysate supernatant was subjected to ultracentrifugation at 80,000 rpm in
a TLA-120.2 rotor for 30 min using an Optima Max-XD Ultracentrifuge (Beckman
Coulter). Supernatant was collected and pellet was re-suspended in equal volume of lysis
and RIPA buffer. Supernatant and pellet fractions were subjected to SDS-PAGE and
immunoblotted using GFP antibody (Roche).
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3.5

Discussion

Previous studies have demonstrated Hsp31 is a multitasking protein involved in several
cellular pathways ranging from functioning as a glutathione independent
methylglyoxalase to stress responder that acts as a molecular chaperone. In this study, we
have established the inhibitory role of Hsp31 in Sup35 prion formation and its
collaboration with Hsp104 to prevent prion aggregation and toxicity in yeast. In the [PSI+]
prion strain, soluble Sup35 protein is depleted into insoluble prion aggregates, hence, it is
no longer functional resulting in nonsense suppression. The stronger [PSI+] prion
phenotype is associated with larger amounts of protein aggregates. Overexpression of
Sup35 PrD-EYFP in a [psi-] strain efficiently induces de novo [PSI+] prion formation and
resulting aggregates, which appear as a peripheral ring associated with the vacuoles. The
first step in de novo prion induction is the formation of a single prion seed, also known as
a “propagon”. These seeds sequester the soluble Sup35 and grow at both ends into larger
aggregates that appeared as rings or dots under microscopy. Moreover, it has been
suggested that not all cells with fluorescent aggregates will transform into [PSI+] prions,
rather about 50% of the cells with fluorescent foci will die and some of the aggregatecontaining cells may not possess amyloids (342). Overexpression of Hsp31 in a [psi-]
strain inhibits Sup35 aggregate formation and this was confirmed by flow cytometry and
SDD-AGE. These results validate the previous observation that Hsp31 reduces Sup35
aggregates in the W303 strain (158). In addition, the inhibition of Sup35 aggregation by
Hsp31 could result in the inhibition of prion formation, because the [PIN+] element
required for prion induction is present in this strain. In fact, we observed that
overexpression of Hsp31 results in a significant reduction in prion induction from Sup35-
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PrD overexpression. This only take place efficiently when Sup35-PrD was overexpressed
for a transient period of time and upon longer expression of Sup35-PrD, Hsp31 was
unable to reduce prion induction. Importantly, Hsp31 alone is unable to cure the [PSI+]
prion indicating that it has no disaggregase activity. We postulate that the inability of
curing but the concomitant ability to prevent the formation of de novo Sup35 SDSresistant aggregates suggests that Hsp31 acts early in the process of prion oligomerization
but once larger oligomers are formed it is not further active in preventing prion
propagation (Figure 3.8).
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Figure 3.8 Hsp31 acts early in the prionogenesis process.
Model depicting the intervention of Hsp31 during the prionogenesis process but lack of
involvement in an established chaperone cycle. Hsp31 and Hsp104 physically interact
but it remains to be determined if this interaction is involved in a handoff of substrates.
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Hsp31 may not participate in modulating an established prion cycle by itself but does
appear to have a role in conjunction with Hsp104 because in a strain lacking Hsp31, the
rate of [PSI+] curing was reduced with Hsp104 overexpression. In addition, we showed
Hsp31 overexpression promotes the elimination of [PSI+] by Hsp104. In fact, another
small HSP Hsp26 was shown to potentiate protein disaggregation by Hsp104.
Interestingly, Hsp26 is only active as a disaggregase when it clusters together with the
protein substrate and not after protein aggregation. A factor in considering the
mechanism of action is that Hsp31 and the human ortholog, DJ-1, have protein deglycase
activity (265,292). Prion glycation can occur spontaneously (343) and glycation can
promote the stability of protein aggregates by covalent crosslinking(344) suggesting the
activity of a deglycase may abrogate prion propogation. Deciphering the contribution of
the enzyme activity versus chaperone function of Hsp31 would be revealing of the
biological role of this multi-functional enzyme. We have previously shown that
chaperone activity can be independent of the enzyme activity because overexpression of
an enzymatically inactive Hsp31 mutant prevents the toxicity of α-syn in yeast. While
there is enough evidence to propose Hsp31 acts early in the process of [PSI+] prion
oligomerization process, future investigation of Hsp31 binding to the Sup35 monomer or
other early oligomer and the role of deglycation in inhibiting prion induction would be
further revealing of the mechanism of action.
We eliminated several possible indirect mechanisms for the cooperation of Hsp31 with
Hsp104 including the possibility that disruption of Hsp31 might compromise Hsp104
expression and thermotolerance function (Figure 3.5). Taking into account that deletion
of Hsp31 down regulates the mRNA level of Ssa3, a possible effect of Hsp31 deletion on
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[PSI+] prion curing by Hsp104 could be due to imbalances between Hsp104 and Hsp70
chaperone as these are required for efficient prion curing. However, this cannot be the
case when Hsp31 is co-expressed with Hsp104, as overexpression of Hsp31 does not alter
the level of Hsp70 protein (158).
We also showed that Hsp31 together with Hsp104 significantly reduced Sup35 prion
toxicity. These results indicate that Hsp31 cooperates with Hsp104 to potentiate Sup35
prion disaggregation and thereby prevent toxicity. Intriguingly, previous studies have
shown such cooperation between sHSPs and ATP dependent chaperones as Hsp104 and
Hsp70 (234,241,243). We also observed a significant reduction of Sup35 toxicity by
Hsp31 alone. A number of possible explanations could account for these results such as,
Hsp31 might prevent sequestration of soluble Sup35 into already present larger
aggregates and therefore inhibit toxicity. We have previously demonstrated that Hsp31
can reduce oxidative stress in cells (158) and this may be the reason for the rescue of
toxicity.
Intriguingly, we also found that Hsp31 physically interacts with Hsp104. Hsp104 is
known to interact with Ydj1, and co-chaperones of Hsp90; Sti1 and Cpr7 (40,225).
Interestingly, Sti1 and Cpr7 are not required for Sup35 prion propagation but deletion of
either of these reduced the Sup35 prion curing by Hsp104. Hsp31 has been documented
to interact with the yeast Hsp90, Hsp82 (345), based on affinity-mass spectrometry hence
the interaction may involve a bridging chaperone such as Hsp90. However, our data is
the first demonstration of Hsp31’s interaction with Hsp104 and could mean these
chaperones may pass substrates to each other. Although the molecular details of the
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interaction are unknown, the involvement of Hsp31 in the prion modulation process and
the apparent close functional cooperation with Hsp104 is an important step in
understanding the biological roles of this multi-tasking protein.
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CHAPTER 4. CONCLUSION AND FUTURE DIRECTIONS

4.1

Summary

Numerous human pathologies are associated with protein misfolding and aggregation
including several neurodegenerative diseases such as AD, PD and prion diseases. For
each such disease a different misfolded protein is responsible for neurodegeneration at
different regions of the brain that leads to differential clinical effects. Although there is
extensive understanding of these molecular mechanisms, there are still numerous
unanswered questions. Several studies show the protective role of HSPs in misfolding
processes that function as chaperones in modulating protein aggregation and their
involvement in neurodegenerative diseases. In this thesis, we used yeast as a model
system to gain insight into the role of Hsp31 as a molecular chaperone and characterized
its function in PD and prion modulation in yeast.
4.2

What makes Hsp31 a multifunctional chaperone protein? What is the role of the
C138 residue in catalytic triad of Hsp31?

An emerging view is that Hsp31 and its associated superfamily members each have
divergent multitasking functions that have the common theme of responding and
managing various types of cellular stress. Hsp31 is involved in multiple cellular functions
including oxidative stress sensing, chaperone and detoxifying enzyme activities such as
functions as methylglyoxalase and deglycation. In chapter 2, we have shown that
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protective role of Hsp31’s chaperone activity can operate independent of detoxifying
enzyme activities in preventing the early stages of protein aggregate formation and
associated cellular toxicities. The catalytic triad present in the DJ-1 superfamily members
is the most common feature, mutation of which can lead to functional variation and
destabilization of dimerization.
In this thesis we showed that Hsp31 is capable of acting as a chaperone without
involvement of its enzymatic activity. Hsp31 possesses a conserved cysteine residue
C138 that is present in different species (272). Previously, it was shown that mutation in
C138 abrogates its enzymatic activity. However, in this thesis, we provide strong
evidence that mutation of C138 has no effect on the chaperone activity of Hsp31. Future
studies should be performed to further delineate the role of C138 in Hsp31. In DJ-1, the
oxidative state of C106 is involved in redox sensing, and the mutation of it destabilizes
the DJ-1 functions. Under oxidative stress condition DJ-1 homo-dimer destabilizes and
therefore loss its protective effect (346,347). Similarly, Hsp31 exists predominantly as a
homo-dimer in solution as shown previously (271,272), and it would be interesting to
determine what is the role of dimerization state in the chaperone activity of Hsp31? It
remains to be determined, what are the chaperone active sites, if C138 has a limited role
in chaperone function? Furthermore, in chapter 3 we provide significant evidence that
Hsp31 is involved in the modulation of prion aggregation, however, we never tested the
effect of C138 mutation in these experiments. Studying these questions will provide a
further mechanistic insight into the role of Hsp31 as a chaperone protein.
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4.3

What is the link between Hsp31 deglycase activity and aggregation activity?

It is now well established that Hsp31 is a molecular chaperone that intervene in the
aggregation of a broad range of protein substrates. Our studies provide strong evidence to
delineating that Hsp31 intervenes early in the process of protein aggregation to prevent
larger aggregate or oligomer formation. Future studies will need to focus on dissection of
the mechanistic details of how Hsp31 prevents the formation of aggregates. Recent
studies showed that enzymatic activity of Hsp31 is capable to deglycate the damaged
proteins. One hypothesis is that Hsp31 binds to damaged or glycated substrate protein to
deglycate them and therefore prevent the formation of aggregates caused by glycation of
the monomeric proteins. It will be important to study that if Hsp31 binds to glycated
monomeric protein and therefore prevent further aggregation of protein. It is not clear if
MGO or glycated proteins are the prime substrate for Hsp31 or if both are important
hence, determination of the in vitro enzymatic activities of Hsp31 on these two different
substrates is important to determine. Further in vivo studies that explore the effect of
Hsp31 on glycated proteins will be needed to provided insight into the mode of action
and reveal the natural substrate(s) of Hsp31 with respect to its
methylyglyoxalase/deglycase activities.
4.4

Determine the role and nature of the Hsp31 and Hsp104 interaction? What are the
roles of Hsp82/Hsp70 and other co-chaperones in conjunction with Hsp31?

In chapter 3 we showed that Hsp31 cooperates with Hsp104 to prevent Sup35 prion
aggregation. Future studies will focus on the nature of interaction between Hsp31 and
Hsp104. Although, we have shown that Hsp31 can pull down endogenous levels of
Hsp104, it is not known if this interaction is direct based on the co-immunoprecipitation.

151
In order to determine if the interaction is direct, in vitro binding assays using recombinant
proteins would answer this question. If these two chaperones interact directly, we can
further explore the interaction sites or regions important for such an interaction.
Information on how the DJ-1/Hsp31 protein family interacts with other chaperones or cofactors is severely lacking. Furthermore, identification of direct interaction sites would
allow a dissection and assessment of the role of this interaction on the overall activity of
Hsp104 or Hsp31? Based on affinity-mass spectrometry, it has been documented
previously, that Hsp31 interacts with the yeast Hsp90, Hsp82. It is also known that
Hsp104 interacts with co-chaperones of Hsp90 hence, the interaction between Hsp104
and Hsp31 may require a bridging chaperone as Hsp90 or its co-chaperones; Sti1 and
Cpr7. Alternatively, Hsp31 maybe a co-chaperone of Hsp90 or Hsp104 and may deliver
substrates to these other chaperones as part of an overall multi-step chaperone cycle.
4.5

Functional diversity or overlap among Hsp31 paralogs in yeast.

The Hsp31 mini-family is composed of four paralogs; HSP31 (YDR533C), HSP32
(YMR322C), HSP33 (YOR391C), and HSP34 (YPL280W). Genes of the Hsp31 mini
family are located at the subtelomeric region of the genome in Saccharomyces cerevisiae.
HSP31 is considered the parental gene with HSP32, HSP33 and HSP34 originating from
it during gene duplication events. Among all the members of this mini-family, Hsp31 is
most divergent and shares approximately 70% homology with the other members of the
family those possess more than 90% homology between them. All the members of Hsp31
family contain the same Cys-His-Glu catalytic triad including the E. coli ortholog.
Previously, it was shown that mutation in the catalytic triad largely abolishes glyoxalase
activity but this catalytic triad is not required for chaperone activity of Hsp31. These
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results indicate that the anti-aggregation activity of Hsp31 is not under the influence of its
enzymatic activity rather, it has a direct chaperone activity against misfolded proteins.
Intriguingly, all the paralogs of the Hsp31 minifamily possess comparable activity against
α-syn aggregation and toxicity when they are overexpressed from the GAL promoter.
However, unlike Hsp31, the other paralogs possess very little methylglyoxalase activity
and are unable to protect the cells from glyoxal toxicity (260,348). These results support
the notion that anti-aggregation activity of Hsp31 mini-family is independent of its
enzymatic activity. Furthermore, all the members of the Hsp31 family contain the same
catalytic triad required for methylglyoxalse activity but so far only Hsp31 is determined
as the most active enzyme in vitro and in vivo. Despite the presence of the catalytic triad
Hsp34 is found to be a very weak methylglyoxalase, which indicates that other regions in
the protein sequence are also important for enzymatic activity. Hsp31 and Hsp34’s
divergent activity has only been shown for MGO, and the different paralogs could have
differential activity depending on the substrate type. In future research, it will be
important to determine the functional diversity between paralogs of Hsp31 in term of its
methylglyoxalase and other enzymatic activities. As, the lack of methylglyoxalase
activity in one of the paralogs is evidence that the paralogs are diverging but additional
studies dissecting the roles within this paralog group are needed to further uncover these
diverging functions. It is also important to note that other biomolecules such as nucleic
acids are also susceptible to oxidative damage and could also be substrates for the Hsp31
protein family.
In contrast, the chaperone activity of Hsp31 and its paralog are comparable (106). Also,
the chaperone activity of Hsp31, Hsp32 and Hsp33 against a cytoplasmic aggregation-

153
prone protein is independent of their role in oxidative stress response and the vacuolar
degradation pathway (262). It would be interesting to study the functional overlap of
these family members. The Hsp31 protein family is broadly spread across fungal species
with varying levels of paralog duplications and additional evidence of divergence
including differences in localization in the Schizosaccharomyces pombe Hsp31 family
members (272).

4.6

Conclusion

In conclusion, study presented here significantly contributed to understand the molecular
role of Hsp31 as a chaperone in protein misfolding diseases. Hsp31 promotes cell
survival under different stress conditions by participating in multiple cellular pathways.
Although, currently we know that Hsp31 is a multifunctional stress responder chaperone
proteins that have homologs in almost every organisms, the exact molecular mechanism
of Hsp31 remains enigmatic. Further studying the mode of action of Hsp31 provides a
promising model to understand the cytoprotective functions of DJ-1 that can be a
potential target for neurodegenerative disease as PD.
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APPENDICES
Appendix A Overexpression of Hsp31 under native promoter in yeast
Proteins under different plasmid system exhibit differential expression and therefore
influence their activities. Most of the studies performed in this thesis are by expressing
Hsp31 under GPD promoter using pAG415-GPD-Hsp31-DsRed. This plasmid expressed
a steady state level of Hsp31 in different yeast strains. Next we ask if Hsp31 under its
native promoter can also overexpress the similar level of Hsp31 in different yeast strains.
We cloned Hsp31 native promoter into pESC-Leu plasmid by replacing the GAL
promoter. This is a 2 µ plasmid that contains myc tag attached to the Hsp31. We
transformed this plasmid into W303 and BY4741 yeast strains. Successful transformants
were selected and cells were allowed to grow into SD-Leu liquid media O/N. Next day,
yeast cell lysate were prepared and subjected to western blots for analysis of protein
expression. Hsp31 was detected by blotting the membrane with myc antibody (Sigma).
For positive control, we used pESC-Leu original plasmid under GAL promoter expressing
Hsp31-myc (Figure A1). We find this plasmid is expressing steady state level of Hsp31
in both strains therefore it provides a useful tool to obtain Hsp31 expression under native
condition.
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Figure A1. Hsp31 expression under native promoter.
W303 and BY4741 yeast cell lysate harboring pESC-Leu-p-Hsp31-myc were prepared
and subjected to western blots for analysis of protein expression. Hsp31 was detected by
blotting the membrane with myc antibody (Sigma). For positive control, we used pESCLeu original plasmid under GAL promoter expressing Hsp31-myc.
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Appendix B Hsp31 pull down for partner proteins
In order to further elucidate the mechanism of Hsp31 in preventing aggregation and to
narrow down its other possible role first it is important to determine the cellular
substrates of Hsp31 that we predict are either oxidatively damaged proteins or chaperones
or both. We proposed to take the approach to use a strain with endogenously tag Hsp31
with 9myc. We used this strain to affinity purify Hsp31 using agarose beads. Clear lysate
obtained from this strain was incubated with anti-myc agarose beads overnight at 4°C
with shaking. Successful pull down was confirmed by running a SDS-PAGE gel and
staining with Sypro Ruby stain followed by western blot using specific anti-myc antibody
(Figure B1). To increase the possibility of identifying Hsp31 client interactions we
digested the protein pull down on beads directly and subjected to mass spec analysis
(Table A1). Proteins that were present in a control sample (non-tagged strain lysate) or
with fewer peptide or spectral counts were removed and the final list is displayed in
Table 1. Hsp31 was the most predominantly identified protein and Hsp31 paralogs
(Hsp32 and Hsp33) were also identified. Potential co-chaperones were also observed
including several Hsp70 isoforms and Hsp104. We performed further verification of
some of these interactions by using various pull down experiments but results remains
inconclusive except for interaction between Hsp31 and Hsp104 that is described in
Chapter 3. For rest of the potential client proteins we performed pull down assay by
transforming client protein under MORF plasmid system into Hsp31-9myc tagged yeast
strain. First we performed the immunoprecipitation of Hsp31 by using myc tagged
agarose beads and subjected to western blot using anti HA antibody. Most of the clients
proteins showed positive signal that could be the reason of non specific binding of the
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protein to agarose beads as these constructs are tagged with protein A along with HA
(Figure B2). In fact, we confirmed that possibility by using the WT stains without 9myc
tagged Hsp31 was still able to bind with the proteins (Figure B3). Due to high affinity of
protein-A binding with agarose beads we could not processed these experiments further.
Next, we proposed to use another technique by using purified GST-Hsp31 protein and
incubating it with lysate generated from cells (Hsp31-9myc) expressing client proteins
under MORF system. After incubation, samples were subjected to SDS-PAGE and
blotted with either GST or myc antibody. This experiment shows clear positive
interaction between Hsp31 and Hsp32 that was used as positive control. All other client
proteins came back negative (Figure B4). Based on these experiments none of the tested
client proteins directly interact with Hsp31 however, it is needed to confirm by using
other plasmid system such as Tap tagged. We also suspect that some of
Hsp31interactions with client proteins are transient in nature and different experimental
conditions are necessary to detect such interactions. Further verification of these
interactions and their role in the function of hsp31 will be pursued in future.
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Table B1 Hsp31 partner proteins identified by combination of Pull down using agarose
beads and affinity mass spec analysis.
Protein Name

Protein

Peptide

Spectral

MW

Accession #

count

count

KDa

Hsp31

gi|45270564

18

600

25

Enolase II, a phosphopyruvate

gi|323337363

14

37

46

gi|151944335

14

35

66

gi|323302648

15

15

22

gi|6323002

9

11

102

≠Mitochondrial porin

gi|151944477

9

13

31

DNA Polymerase

gi|323348993

8

10

124

*Hsp33

gi|323350061

7

25

25

gi|173166

7

11

_

gi|190613718

6

8

77

gi|6321024

6

14

127

gi|323337248

5

8

155

gi|323308952

5

19

89

hydratase
*Stress-seventy subfamily B
protein
Fatty Acid Synthetase
*Chaperone ATPase HSP104

Voltage-dependent anionselective channel
*A Complex Of Sse1p And
Hsp70
ExtraCellular Mutant ECM
(DNA dependent ATPase)
Ribosomal 60S subunit protein
L27B
Subunit of Elongator complex
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Table B1 continued
Mdl2p, Mitochondrial inner

gi|259149887

5

13

85

gi|323308411

5

4

35

gi|172066

4

6

44

gi|323309019

4

6

44

gi|323305941

4

4

69

gi|151943468

4

4

35

gi|323345814

3

18

25

gi|6325449

3

3

40

gi|151945807

3

14

_

Vacuolar Protein Sorting 4

gi|158430364

2

26

48

Transcription initiation Factor

gi|323305366

1

145

72

gi|6322694

1

67

72

membrane transporter
GAPDH, isozyme 1 (Tdh1)
Mitochondrial outer
membrane (OM45)
Mitoch phosphatidate
cytidylyltransferase (Tam41)
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Figure B2. Pull down of Hsp31 using HSP31-9myc strain
(A) Immunoprecipitation (IP) of Hsp31 from HSP31-9myc genomically tagged strain
with overexpression of Hsp90, Hsp70 and Hsp33 under MORF plasmid expression
system. IP was performed using myc conjugated agarose beads followed by WB using
HA antibody. (B) IP of MORF Sup35, Las17, Hsp10, Eno1 and Hsp32 that are
transferred and overexpressed in Hsp31-9myc genomically tagged strain. IgG sepharose
beads was use to pull down protein-A tagged attached to these proteins. Samples were
separated on 10% SDS-PAGE gel and immunoblotted using myc antibody.
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Figure B3. Hsp31 pull down using WT and HSP31-9myc strain.
(A) Immunoprecipitation (IP) of Hsp31 from HSP31-9myc genomically tagged strain
harboring MORF plasmid expressing Ssa2 or Eno1. WT strain was included as negative
control. IP was performed using myc conjugated agarose beads followed by WB using
HA antibody. (B) Immunoprecipitation (IP) of Hsp31 from Hsp31-9myc genomically
tagged strain harboring MORF plasmid expressing Hsp26 or Hsp82. WT strain was
included as negative control. IP was performed using myc conjugated agarose beads.
Samples were subjected to WB and immunoblotted using HA antibody.
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Figure B4. Immunoprecipitation of purified GST-Hsp31 with lysate.
Hsp31-GST was purified from E coli and incubated with the yeast lysate generated from
cells with genomically tagged 9myc-Hsp31 and expressing MORF Ssa4, Ssa3, Hsc82,
Hsp60, Hsp26, Las17 and Hsp32 for 2 hrs. Samples were separated on 10% SDS-PAGE
and immunoblotted using either GST (upper panel) or myc antibody (lower panel). Only
positive control Hsp32 was pull-down.
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